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ABSTRACT OF THESIS 
 
 
 
 
BONE ENGINEERING OF THE ULNA OF RABBIT 
 
 
 
Repair of bone defects is a major challenge in orthopaedic surgery.  Current bone graft 
treatments, including autografts, allografts and xenografts, have many limitations making 
it necessary to develop a biomaterial to be a bone graft substitute. One such biomaterial is 
bioactive resorbable silica-calcium phosphate nanocomposite (SCPC).  SCPC was 
processed using a 3D rapid prototyping technique and sintered at different temperatures 
to create porous scaffolds.  SEM analyses and mercury intrusion porosimetry showed 
SCPC to be highly porous with micro- and nanopores. BET analysis indicated that SCPC 
had high surface area.  Mechanical testing demonstrated that SCPC had a compressive 
strength similar to trabecular bone.  Analysis of different thermal treatment temperatures 
indicated as the temperature was increased, the porosity decreased and the mechanical 
strength increased. When loaded with rhBMP-2 (SCPC-rhBMP-2), SCPC provided a 
sustained release profile of rhBMP-2 for 14 days.  This was shown to be a greater release 
than hydroxyapatite (HA)-rhBMP-2.  After immersion in SBF, ICP analyses showed the 
calcium concentration of SBF dropped drastically after one day of immersion.  In 
conjunction, FTIR showed the formation of a hydroxyapatite layer on the SCPC surface 
and was confirmed by SEM.  SCPC thermally treated at 850 ºC demonstrated the greatest 
dissolution/precipitation reactions when immersed in SBF.  Processing the SCPC-
rhBMP-2 hybrid using a rapid prototyping technique allowed for an exact replica of the 
rabbit ulna to be fabricated.  This was implanted into a 10 mm segmental defect in the 
rabbit ulna.  CT scans during the healing of the defect showed intimate union between 
SCPC-rhBMP-2 and the bone and about 65% healing of the defect after 4 weeks.  Rabbits 
were euthanized after 12 and 16 weeks.  Digital images show almost complete healing of 
the defect after 16 weeks.  Torsional testing of the ulna after 12 weeks demonstrated 
restoration of maximum torque and angle at failure.  Histological evaluation after 12 
weeks showed the regenerated bone has all the morphological characteristics of mature 
bone.  Through in-vitro and in-vivo testing, it can be recommended that the porous 
bioactive SCPC can serve as a successful delivery system for biological growth factors 
and serve as an alternative to autologous bone grafting. 
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KEYWORDS: tissue engineering scaffold, nanocomposite, bone morphogenetic protein-
2, segmental defect, bone regeneration 
 
Multimedia Elements Used: MPEG (.mpg) 
                Amanda Peter Hart   
 
             04/21/05   
Copyright © Amanda Peter Hart 2005 
 
 
 
 
 
 
 
 
 
 
 
BONE ENGINEERING OF THE ULNA OF RABBIT 
 
 
 
 
By 
 
Amanda Peter Hart 
 
 
 
 
 
 
 
 
 
 
 
 
 
            Dr. Ahmed El-Ghannam   
                (Director of Thesis) 
 
             Dr. Abhijit Patwardhan   
       (Director of Graduate Studies) 
 
              04/21/05   
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
RULES FOR THE USE OF THESES 
 
 
Unpublished theses submitted for the Master’s degree and deposited in the 
University of Kentucky Library are as a rule open for inspection, but are to be 
used only with due regard to the rights of the authors. Bibliographical references 
may be noted, but quotations or summaries of parts may be published only with 
the permission of the author, and with the usual scholarly acknowledgments. 
 
Extensive copying or publication of the thesis in whole or in part also requires the 
consent of the Dean of the Graduate School of the University of Kentucky. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
THESIS 
 
 
 
 
 
 
 
 
 
 
 
Amanda Peter Hart 
 
 
 
 
 
 
 
 
 
 
The Graduate School 
 
University of Kentucky 
 
2005 
 
 
 
 
 
 
 
 
 
BONE ENGINEERING OF THE ULNA OF RABBIT 
 
 
 
 
 
 
 
       
 
THESIS 
       
 
A thesis submitted in partial fulfillment of the 
requirements for the degree of Master of Science 
 in Biomedical Engineering 
 in The Graduate School 
at the University of Kentucky 
 
 
 
By 
 
Amanda Peter Hart 
 
Lexington, Kentucky 
 
Director: Dr. Ahmed El-Ghannam, Professor of Biomedical Engineering 
 
Lexington, Kentucky 
 
2005 
Copyright © Amanda Peter Hart 2005 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DEDICATION 
 
This thesis is dedicated to my mom for her patience and understanding for the last 24 
years.  She has stood by my side in thick and thin.  Without her I do not think I would 
have gotten this far in life.  I want her to know that all of my hard work is because of her.  
Her help and support has been invaluable and I am eternally grateful.   
 
ACKNOWLEDGMENTS 
 
For the last two year, the research and writing of this master’s thesis has taken over my 
life.  As much as I have fought it, it has become my life.  And I am grateful for that.  I 
have learned so much from so many great people and I would like to take this opportunity 
to thank them.  Dr. Ahmed El-Ghannam, my thesis advisor, who never gave up on me, 
thank you for giving me the opportunity to work on this project and for the help and 
guidance that has been extended to me during the last two years.  Thanks to Dr. Larry 
Cunningham for his surgical expertise and his abundant sense of humor.  To Dr. Dean 
White, thank you for your help with the histology and I am sorry for always bugging you 
to get done.  Thanks to Patty Lott at the University of Alabama-Birmingham for her help 
with the histology.  For their help with the mechanical testing, I would like to thank Dr. 
Marwan Khraisheh and Fadi Abu-Farha.  The DLAR staff has been great to work with 
and they helped out tremendously with the rabbits and the surgeries.  Special thanks to 
Samantha Otte for all her help with the rabbits and always returning emails.  I wish to 
acknowledge Larry Rice, “the SEM guy”, for his help with my samples and the great 
discussions about Kentucky football.  Thanks to the people at Micromeritics for 
analysing my samples.  I want to thank the engineers at CRMS for helping process my 
samples.  Thanks to Dr. Congqin Ning, Junaid Mehta, and Gautam Gupta for their help 
and patience in the lab and for teaching me so much.  Thank you to Dr. David 
Pienkowski and Brock Marrs for letting me used their lab equipment for the torsional 
testing.  To the wonderful Diagnostic Radiology department at UK Chandler Medical 
Center, thank you for the help with the CT scans and for always finding a way to squeeze 
us in to your busy schedule.  I want to thank Spunky the rabbit, for if it wasn’t for him 
none of this could have been possible.  For his sacrifice, we were able to make this study 
a huge success.   Thanks to Jessica Sharon for her support through all this.  At times it 
seems like she was the only one who understood what I was going through.  
Congratulations to her for surviving all this along side of me.  Finally, I owe all of my 
achievements to my family, my mom Pam Hart, my sisters Stacy McClure and Jody 
Osisek, and my nieces and nephew Emilee, Nathaniel, and Kristina McClure.  Without 
their support, I would not have been able to complete this thesis. 
 iii
TABLE OF CONTENTS 
 
ACKNOWLEDGMENTS ................................................................................................. iii 
 
LIST OF TABLES............................................................................................................ vii 
 
LIST OF FIGURES ......................................................................................................... viii 
 
Chapter 1: Introduction ....................................................................................................... 1
1.1 Bone Grafts ............................................................................................................... 1 
1.1.1 Autografts .......................................................................................................... 1 
1.1.2 Allografts and Xenografts.................................................................................. 2 
1.1.3. Synthetic Grafts ................................................................................................ 3 
1.1.3.1 Bioceramics................................................................................................. 3 
1.1.3.2 Polymers ..................................................................................................... 3 
1.1.3.3 Metals.......................................................................................................... 4 
1.1.3.4 Composites.................................................................................................. 4 
1.2 Tissue Engineering.................................................................................................... 5 
1.2.1 Growth Factors................................................................................................... 5 
1.2.2 Ideal Characteristics of BMP carrier.................................................................. 6 
1.2.3 Current BMP Carriers ........................................................................................ 8 
1.2.3.1 Collagen ...................................................................................................... 8 
1.2.3.2 Polymers ..................................................................................................... 9 
1.2.3.3 Calcium Phosphates .................................................................................... 9 
1.2.3.4 Bioactive Glasses ...................................................................................... 10 
1.2.3.5 Composites................................................................................................ 11 
1.2.3.5.1 Silica-Calcium Phosphate Composite................................................ 11 
1.3 Processing and Fabrication of Tissue Engineering Scaffolds................................. 12 
1.3.1 Rapid Prototyping Technologies...................................................................... 12 
1.3.1.1 Fused Deposition Modeling...................................................................... 13 
1.3.1.2 Selective Laser Sintering .......................................................................... 13 
1.3.1.3 Three-Dimensional Printing...................................................................... 14 
1.3.1.2.1 Z-Corp Processing ............................................................................. 14 
1.4 Objectives ............................................................................................................... 15
 
Chapter 2: Materials and Methods.................................................................................... 16
2.1 In-Vitro Study ......................................................................................................... 16 
2.1.1 Sample Preparation .......................................................................................... 16 
2.1.2 Z-Corp Processing ........................................................................................... 16 
2.1.3 Effect of Thermal Treatment ........................................................................... 18 
2.1.4 Material Characterization................................................................................. 20 
2.1.4.1 Surface Characterization........................................................................... 20 
2.1.4.2 Porosity Measurements............................................................................. 20 
2.1.4.3 Mechanical Properties............................................................................... 21 
2.1.4.4 Evaluation of Release Kinetics of rhBMP-2............................................. 21 
2.1.4.4.1 Recombinant Human BMP-2 Preparation ......................................... 21 
 iv
2.1.4.4.2 Release Kinetics of rhBMP-2 ............................................................ 22 
2.1.5 Study of the Interaction of SCPC with Simulated Body Fluid ........................ 23 
2.1.5.1 Preparation of Simulated Body Fluid ....................................................... 23 
2.1.5.2 Immersion Study....................................................................................... 23 
2.1.5.3 SCPC Dissolution Kinetics ....................................................................... 23 
2.1.5.4 Surface Chemistry Analysis...................................................................... 25 
2.1.5.5 Surface Modification ................................................................................ 25 
2.2 In-Vivo Study .......................................................................................................... 26 
2.2.1 Experimental Setup.......................................................................................... 26 
2.2.1.1 General Experimental Protocol................................................................. 26 
2.2.1.2 Prototype Processing................................................................................. 26 
2.2.1.3 Thermal Treatment.................................................................................... 32 
2.2.1.4 Sterilization............................................................................................... 32 
2.2.1.5 Construct of SCPC-rhBMP-2 Scaffold..................................................... 32 
2.2.1.6 Surgery...................................................................................................... 33 
2.2.2 Evaluation of SCPC-rhBMP-2 Graft ............................................................... 33 
2.2.2.1 Radiographic Evaluation........................................................................... 33 
2.2.2.2 Histology................................................................................................... 34 
2.2.2.3 Torsional Testing ...................................................................................... 34 
2.3 Statistical Analysis.................................................................................................. 36 
 
Chapter 3: Results ............................................................................................................. 37
3.1 Material Characterization........................................................................................ 37 
3.1.1 Morphology analysis........................................................................................ 37 
3.1.2 Porosity Measurements.................................................................................... 37 
3.1.3 Mechanical Testing.......................................................................................... 43 
3.1.4 Release Kinetics of rhBMP-2 .......................................................................... 45 
3.2 Interaction of SCPC with SBF................................................................................ 45 
3.2.1 ICP ................................................................................................................... 45 
3.2.2 FTIR................................................................................................................. 52 
3.2.3 Surface Modification ....................................................................................... 53 
3.3 SCPC-rhBMP-2 Hybrid Implantation..................................................................... 55 
3.3.1 Radiographs ..................................................................................................... 55 
3.3.2 Histology.......................................................................................................... 65 
3.3.3 Torsional Testing ............................................................................................. 65 
 
Chapter 4: Discussion ....................................................................................................... 69
4.1 In-Vitro.................................................................................................................... 69 
4.1.1 Material Characterization................................................................................. 69 
4.1.1.1 Hydroxyapatite Layer ............................................................................... 71 
4.1.1.2 Mechanical Strength ................................................................................. 72 
4.1.1.3 Geometry................................................................................................... 73 
4.1.2 rhBMP-2 Release Kinetics............................................................................... 73 
4.1.3 Interaction of SCPC with SBF......................................................................... 74 
4.1.3.1. Effect of Immersion Duration.................................................................. 74 
4.1.3.2 Effect of Thermal Treatment Temperature ............................................... 77 
 v
4.2 In-Vivo..................................................................................................................... 78 
4.2.1 Radiographs ..................................................................................................... 79 
4.2.2 Histology.......................................................................................................... 79 
4.2.3 Torsional Testing ............................................................................................. 80 
 
Chapter 5: Conclusion....................................................................................................... 82
 
REFERENCES ................................................................................................................. 83 
 
VITA................................................................................................................................. 87
 
 
 vi
LIST OF TABLES  
 
Table 2.1.1: Chemical Composition of SCPC and HA in mol %..................................... 17 
 
Table 2.1.5.1:  Simulated Body Fluid Concentrations...................................................... 24 
 
Table 3.1.2:  Porosity Analysis ......................................................................................... 42 
 
Table 3.1.3:  Mechanical Properties Results..................................................................... 44 
 
Table 3.3.3:  Torsional Testing Results ............................................................................ 68 
 
 
 
 vii
LIST OF FIGURES 
 
Figure 2.1.2: Video of Z-Corp Processing........................................................................ 19 
 
Figure 2.2.1.2 (a-f): Z-Corp Processing............................................................................ 27 
 
Figure 3.1.1 (a-d): SEM Micrographs Before Immersion ................................................ 38 
 
Figure 3.1.4:  Cumulative Release of rhBMP-2 from SCPC and HA .............................. 46 
 
Figure 3.2.1 (a-d): ICP Results ......................................................................................... 47 
 
Figure 3.2.2 (a-c): FTIR Results ....................................................................................... 53 
 
Figure 3.2.3 (a-f): SEM Micrographs After Immersion ................................................... 56 
 
Figure 3.3.1 (a-d): Radiographic Evaluation .................................................................... 62 
 
Figure 3.3.2 (a-b): Histological Analysis.......................................................................... 66 
 
 
  
 
 
 
  
 viii
Chapter 1 
Introduction 
 
1.1 Bone Grafts 
 
Skeletal deficiencies that result from trauma, tumors or abnormal development frequently 
require surgical intervention in order to restore normal tissue function [1]. In the US 
alone there are over 2.2 million orthopaedic procedures performed each year, 450,000 of 
those being bone graft procedures. This makes bone the most common tissue for 
transplant procedures, second only to blood [2].   Although current surgical treatments 
are often successful in repairing bone defects, they all have problems and limitations. 
 
Bone grafts are needed when part of your body is missing bone. This missing portion of 
bone is frequently called a bone defect. A bone graft is a surgical procedure that replaces 
the bone defect with material from the patient's own body or an artificial, synthetic, or 
natural substitute. The purpose of the graft is not only to replace the missing bone, but 
also to stimulate new bone formation in the bone defect area [3]. The graft forms a bridge 
and acts a scaffold in the defect area until new bone can grow in its place.  Eventually the 
newly formed bone should completely replace the bone graft material.   
 
1.1.1 Autografts   
 
Currently there are three main types of biological bone graft procedures.  The first is the 
autograft, the “gold standard” method for repairing bone [3]. This is where bone is 
harvested from a patient’s own body, typically from the pelvis or iliac crest. Autogenous 
bone grafts provide both osteoinductive and osteoconductive stimuli for bone growth. 
They can be used to not only provide mechanical support but also to stimulate new bone 
formation.  Autogenous bone grafting has excellent fusion rates and has become the 
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standard by which all other bone grafts are measured. Many surgeons prefer autogenous 
bone grafts because there is no risk of the body rejecting the graft since it came from the 
patient's own body.  However, the success of the autograft is often compromised due to 
its many limitations.  These include the fact that removing bone from one part of the 
body creates the same deficit there as in the area being repaired, possible donor site 
morbidity, limited donor bone supply, anatomical and structural problems, high costs, 
and the need for multiple surgeries [3].   
 
1.1.2 Allografts and Xenografts 
 
In an effort to minimize the problems associated with taking the patient's own bone, a 
common alternative to the autograft is the use of allograft or xenograft bone.  An allograft 
bone graft is bone harvested from deceased individuals who have donated their bone for 
use in the treatment of living patients. The advantage of the allograft is that multiple 
surgeries within the same patient are not required.  However, the shortcomings greatly 
outweigh the benefits [2]. The downfalls to the use of allografts are the necessity of 
having compatibility between donor and recipient, it does not promote bone growth very 
well, there is limited donor supply, and diseases may be transmitted together with the 
implant [4].  
 
The third type of biological bone graft is the xenograft.  A xenograft is a graft in which 
bone tissue is taken from another species.  Xenografts are biocompatible and are also 
osteoinductive in nature.  Contrary to the auto- and allograft, xenografts are available in 
almost endless supply.  However, like allografts, xenografts have problems with 
compatibility between donor and recipient, and possible disease transmission. 
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1.1.3 Synthetic Grafts 
 
In order to offer the advantages of the autograft, allograft, and xenogaft and eliminate the 
limitations, it is necessary to develop a biomaterial to be used as a bone graft substitute. 
 
1.1.3.1 Bioceramics  
 
Bioceramics, such as hydroxyapatite (HA), tricalcium phosphate (TCP), and bioactive 
glass (BG), are one type of biomaterial that is being used as synthetic bone grafts. These 
synthetic materials have similar surface structure to that of natural bone, making them 
osteoconductive. Most osteoconductive materials bond to bone and allow direct bone 
deposition on their surface. Synthetic porous bioceramics are primary candidates as bone 
substitutes due to not only their excellent osteoconductive properties, but they are 
available in unlimited supply, and they can have custom-designed shape and size.  They 
are not associated with disease transmission, cause neither chronic inflammation nor 
systemic toxicity, and there is no foreign body response nor any evidence of rejection [5]. 
They are available in many forms such as porous particles and pastes [6]. Although 
ceramics may provide a scaffold for bone growth, they are not osteoinductive, meaning 
they do not have the ability to enhance osteogenic differentiation of osteoblastic cells.  
Also, the application of porous ceramics for load-bearing conditions is difficult due to 
their adverse mechanical properties; they are brittle, have low impact resistance, and have 
low tensile strength [5].  
 
1.1.3.2 Polymers 
 
Polymers such as poly(lactic) acid (PLA), poly(glycolic) acid (PGA), and their co-
polymers (PLGA), and are often used as bone graft substitutes.  These materials have the 
advantage of altering their chemical structure so that they can be integrated with growth 
factors, drugs, and other compounds to create delivery systems.  They are biocompatible, 
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resorbable, can be processed into porous scaffolds that have mechanical properties 
similar to that of bone.  However, some polymers are not osteoconductive and it has been 
found that as certain polymers degrade, they release acidic by-products which can inhibit 
new bone formation and even cause bone resorption [7, 8].  
 
1.1.3.3 Metals 
 
Metals are another type of synthetic biomaterial that can be used as a biomaterial for 
bone defects.  Metals such as titanium and titanium alloys, stainless steel, and cobalt-
chromium have been widely used in the orthopaedic field and can be utilized in load-
bearing conditions.  This is due to their excellent mechanical characteristics in terms of 
stiffness and elasticity and bone compatibility [9]. Conversely, most metals are not 
osteoconductive, and none are osteoinductive, or resorbable.   
 
1.1.3.4 Composites 
 
Composite bone grafts are the combination of multiple biomaterials.  These are used in 
order to maximize the advantages and minimize the limitations of these synthetic graft 
materials. Such combinations of these include ceramic-metal, ceramic-polymer, ceramic-
ceramic.  In combining a ceramic with a metal, the composite can have the mechanical 
strength of a metal while taking on the osteoconductive property of a ceramic.  By 
combining a ceramic with a polymer, the structure of the biomaterial is less brittle than a 
ceramic alone and the polymer can become osteoconductive. Combining different 
biomaterials can create a composite that is porous, resorbable, biocompatible, 
osteoconductive, and has good mechanical strength.  Yet, in developing a biomaterial as a 
bone graft substitute it is not only necessary to fill the bone defect with an 
osteoconductive scaffold, but to seed that scaffold with osteoinductive growth factors that 
will stimulate new bone tissue to grow in and around the porous scaffold.   
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1.2 Tissue Engineering 
 
Tissue Engineering is a multidisciplinary field that combines the principles of biology 
and engineering to develop tissue substitutes to restore, maintain, or improve the function 
of diseased or damaged tissues, such as bone. Cytokine therapy is one area of bone tissue 
engineering that involves seeding highly porous, biodegradable scaffolds with growth 
factors, then implanting the scaffolds to induce and direct the growth of new, healthy 
bone at a target site [10, 11]. For a scaffold to be used as a tissue engineering scaffold it 
should fulfill three primary purposes [12].  First, it should geometrically replicate the size 
and shape of the defect.  Second, it should temporarily fulfill the physical function of the 
bone tissue it is replacing.  Finally, the scaffold material composition and porous 
microstructure should enhance tissue regeneration.   
 
1.2.1 Growth Factors 
 
Growth factors, such as bone morphogenetic proteins (BMPs) and transforming growth 
factors (TGF-β), are osteoinductive agents that occur naturally in bone.  Growth factors 
are very powerful stimulants for bone formation and can be used alone or with a carrier 
system as graft replacements. These biologically active proteins play a key role in the 
body's own natural bone-forming process and are found naturally at sites of bone 
fracture. These proteins can be produced, concentrated and placed in the body in areas 
where bone formation is needed and are powerful enough to stimulate bone formation 
without the need for taking the patient's own bone.  
 
BMPs are a subgroup of factors in the TGF-β superfamily and consist of a family of at 
least 15 structurally related osteoinductive growth factors.  They were originally 
identified as protein regulators of cartilage and bone formation.  There are several 
different BMPs naturally found in the body and many play a critical role in bone 
formation. The most promising proteins are BMP-2 and BMP-7 [13]. These two proteins 
have been extensively studied in animals and humans with very promising results [14]. 
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Both proteins have shown to successfully stimulate new bone formation in defect sites 
and with higher success rates when used alone as compared to using the patient's 
autogenous bone graft. They accomplish this by inducing differentiation of stem cells 
into osteogenic bone forming cells.  
 
Recombinant human bone morphogenetic protein-2 (rhBMP-2) is a substance that was 
cloned by Wozney et al. [15]. rhBMP-2 stimulates the expression of differentiation 
markers of osteoblasts in-vitro [16] and initiates a complex series of cellular events 
culminating in bone formation [17]. Although BMP can induce bone formation at a 
defect site alone, due to its short half-life, rapid diffusion and degradation [16] the dose 
needed to induce this bone formation can be quite high. This dose can be greatly reduced 
when BMP is combined with an appropriate biodegradable scaffold carrier that can 
immobilize the protein while retaining its bioactivity [18]. In addition to reducing the 
dose needed for bone induction, a carrier acts as a means of deployment for BMP.  By 
attaching BMP to a delivery system, the bioactivity of the protein can be maintained for a 
longer period of time and the protein can be held in place at the target site [11]. A carrier 
must not inhibit the bone formation and bone repair capability of the BMP [11]. When 
used with a biomaterial carrier system, BMP has been shown to stimulate bone 
formation, alkaline phosphatase activity, collagen synthesis, and osteoblast differentiation 
[19].   
 
1.2.2 Ideal Characteristics of BMP Carrier 
 
One of the major functions of a delivery system for BMPs is to retain BMP at the grafted 
site for a period of time sufficient to induce bone [20] so that the molecules can exert 
their biological action.  Therefore, a carrier should have controlled release kinetics of 
BMP, meaning it has the ability to deliver the growth factor at the appropriate time and in 
the proper dose [14].  
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Another major function is to provide an initial substratum for the growth and 
differentiation of bone-forming cells.  In order to be this initial substratum, a bone tissue 
engineering scaffold must possess certain characteristics.  First of all, the tissue 
engineered scaffold should be biocompatible and not elicit an inflammatory or 
immunogenic response in the body [20].  
 
An ideal biomaterial carrier should also be highly porous providing a pathway of 
interconnections through which new cells can migrate and new blood vessels can form. If 
the pore size of the biomaterial exceeds 100 µm, bone will grow within the 
interconnecting pore channels near the surface and maintain its vascularity and long-term 
viability [21]. Although, for a resorbable material, the immediate resorption that takes 
place when it is immersed in a physiological solution will increase its pore sizes, 
eliminating the need for the initial porosity of the biomaterial to be specifically defined.  
Nevertheless, the implant should serve as a scaffold for bone formation, maintaining 
surface area and volume to facilitate directional bone formation [22]. A porous scaffold 
also provides an appropriate surface environment in which cells can adhere and 
proliferate.   
 
A biomaterial also needs to be osteoconductive and have the ability to promote bone 
growth by allowing bone formation on its surface.  Biomaterials with good 
osteoconductive properties can form a tight bond with the host bone tissue, a 
characteristic which is desirable for the restoration of bone function at a defect site [20]. 
The biomaterial also should be osteoinductive, stimulating new bone formation. And 
osteoinductive means that the material will enhance osteogenic differentiation of 
osteoblatic cells, the cells that will build new bone.  
 
The biomaterial should also ideally be resorbable, so that as new bone grows, the scaffold 
can slowly degrade away and eventually be completely replaced by newly regenerated 
bone [20]. The degradation rate of the biomaterial needs to be controlled so that it does 
not degrade away too quickly before new bone can grow in its place, or too slowly 
inhibiting new bone formation.  In addition, when used as a carrier for BMP, if a 
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biomaterial degrades too fast the BMP may be released too rapidly and the risk of fibrous 
ingrowth, and failure of bone healing, is increased. 
 
In order for the biomaterial to initially replace bone, it needs to exhibit similar 
mechanical properties of bone [21]. If used in a load bearing situation, the scaffold needs 
to possess enough rigidity to be able to withstand the forces that are going to be applied 
to it.  But there is a trade off between porosity, which is important, and mechanical 
strength [5]. As the porosity increases, the mechanical strength is going to decrease.  
There needs to be a balance between the two so that the stimulation of new bone 
formation can be greatest. 
 
Because no bone in the body is a perfect cylinder of rectangle, the geometry of the 
scaffold must also be appropriate for the implantation site, as it will define the area in 
which the bone is formed [11]. A precise geometry is not only important in order to 
achieve maximum restoration of function, but also for cosmetic reasons as well.  This is 
especially true for maxillofacial bone graft procedures.  In addition, since the size and 
shape of an implant can influence the degradation rate of the carrier, the rate of release of 
BMP, and the bonding of bone to the implant, it is essential to have a scaffold that is the 
exact shape of the specific bone defect that it is temporarily replacing.   
 
1.2.3 Current BMP Carriers 
 
1.2.3.1 Collagen 
 
The most common scaffold materials used as BMP carriers include collagen and 
biodegradable polymers [9, 23].  
 
Collagen is a fibrous protein that is abundantly found in the extracellular bone matrix.  
The porous structure of collagen makes it conducive to mineral deposition, vascular 
ingrowth, and growth-factor binding. This structure provides both a physical and 
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chemical environment that is favorable to new bone regeneration.   Absorbable collagen 
sponges have served as carriers for growth factors, limiting the diffusion of rhBMP-2 
through collagen-rhBMP-2 interactions and physical trapping [24].  These interactions 
have assisted in establishing a prolonged release of BMP at the target site.  However, 
collagen provides little or no initial structural support and has potential immunogenicity 
[2].  
 
1.2.3.2 Polymers 
 
Polymers are biomaterials that have been applied in clinical practice in fracture fixation 
for over 20 years. The most popular of the polymers used are PLA, PGA, and PLGA.  
Because of their biocompatibility and their ability to bind proteins, polymers have been 
widely used as scaffolds to deliver BMP. Polymers are a promising material for BMP 
delivery since their chemical structure, and thus its release kinetics of BMP, can be easily 
altered. Polymers can be made into porous, resorbable scaffolds that have the proper 
mechanical strength in order to replace bone. One study reported that encapsulation of 
BMP with a biodegradable PLGA is an effective polymeric vehicle for the controlled 
release of BMP [1].  However studies have shown that as some polymers degrade, 
isolated areas of fragmentation and degradation of the polymer scaffold had elevated 
areas of inflammatory response cells [7, 8]. As polymers degrade they can release acidic 
by-products that have adverse foreign body reactions. 
 
1.2.3.3 Calcium Phosphates 
 
Another major group of biomaterials that are used as carriers for BMP delivery are 
calcium phosphate-based bioceramics.  Calcium phosphates have been used in medicine 
and dentistry for nearly 30 years [22]. They are widely used as bone substitutes due their 
high bioactivity.  They have been known to easily bond to bone and enhance bone tissue 
formation.  Calcium phosphates can be classified as non-resorbable or resorbable.  Two 
of the forms of calcium phosphate ceramics that are most widely used are TCP and HA.  
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Both have similar structures to that of bone and have been shown to be osteoconductive 
[25]. Calcium phosphate ceramics can be processed to be porous scaffolds and because of 
this have been widely used as tissue engineering scaffolds for the delivery of growth 
factors [21, 26-29]. One study investigated a porous calcium phosphate ceramic with 
micro-porous structures, which consisted of HA and a trace of α-TCP, as a BMP carrier 
[29]. Mature lamellar bone was found in the implants after 35 days, indicating the 
calcium phosphate ceramic was an effective carrier of BMP. 
 
Unfortunately, calcium phosphate ceramics also exhibit many limitations. When calcium 
phosphate ceramics have been used as carriers for BMP delivery they have often elicited 
inflammatory and immunologic reactions [30]. It has been found that porous TCP 
ceramics are dissolved and resorbed relatively quickly and do not have good mechanical 
stability [5]. Moreover, this adversely high-dissolution rate has been associated with an 
elicited immunologic response [31]. As for HA, although it has been shown that bone 
does grow in porous and dense HA particulates, the bone conductivity is limited [25]. 
The major limitation in using calcium phosphate ceramics is their poor mechanical 
properties.  They have been shown to be brittle, so when implanted in place of bone there 
is minimal immediate structural support. 
 
1.2.3.4 Bioactive Glasses 
 
Bioactive glass is another calcium-phosphate based bioceramic used to replace bone that 
can be considered as a BMP carrier.  Besides being composed of calcium and 
phosphorus, another major component is silica. Due to its amphorous structure, it is 
known to have a stimulatory effect on bone cell function, making it a favorable bioactive 
biomaterial.  As compared to HA, BG accelerated bone growth 3 times more when 
implanted in bone [32]. Bioactive glasses form a tight bond with surrounding tissues by 
the in-vivo formation of a biologically active carbonate-containing hydroxyapatite layer 
(HCA) on the glass surface. However, BG is a solid non-resorbable material [33]. 
Therefore, when synthesized as a nonporous carrier for the delivery of BMP, the growth 
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factors can only be seeded onto the outside of the BG scaffold.  Upon implantation this 
would cause an immediate release of all the protein.  As discussed before an appropriate 
carrier would retain the BMP at the grafted site for a period of time sufficient to induce 
bone. 
 
1.2.3.5 Composites 
 
Now the previously mentioned carriers all had different characteristics that set them apart 
as possible delivery systems for BMP.  But none of them seemed to have all of the 
qualities necessary to make them that perfect tissue engineering scaffold for BMP 
delivery.  A composite graft can combine different carriers so that the weaknesses of one 
are overridden by the strengths of another.  One example of a composite graft could 
combine an osteoconductive biomaterial with a biomaterial that provides good 
mechanical properties, potentially replicating bone functionality.  One study combined a 
titanium mesh and calcium phosphate ceramic [27]. The titanium mesh provided the 
composite with excellent mechanical properties and biocompatibility.  The calcium 
phosphate coated the titanium mesh and provided the osteoconductivity to the composite.   
Another example of a composite could be a polymer-ceramic composite.  A study 
combined the synthetic biodegradable polymer PLA with interconnected-porous calcium 
HA [10]. This composite combined the strength of the polymer with the 
osteoconductivity of the ceramic.  When implanted in a critical sized defect, the 
composite graft induced new bone formation in the pores and around the implant with 
sufficient strength and anatomical structure. 
 
1.2.3.5.1 Silica-Calcium Phosphate Composite 
 
Another composite biomaterial is the one being used in this study. This composite 
biomaterial has been developed to possess all of the characteristics needed in order to be 
a tissue engineering scaffold for BMP delivery and bone regeneration.  This material is 
SCPC or silica-calcium phosphate composite. This biomaterial is resorbable, porous, and 
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bioactive. Previous studies in our lab have shown that SCPC has superior stimulatory 
affects on bone tissue regeneration when compared to BG or HA ceramic.  Moreover, 
when the material was used as a carrier for BMP, the SCPC-rhBMP-2 hybrid provided a 
sustained release profile of biologically active rhBMP-2 and enhanced mesenchymal 
stem cell differentiation and bone tissue formation in-vitro. 
 
1.3 Processing and Fabrication of Tissue Engineering Scaffolds 
 
Once a biomaterial is found that meets all of the qualifications of a tissue engineering 
scaffold for BMP delivery and bone regeneration, it must be processed into a scaffold.  
For bone tissue engineering, the bone graft substitute needs to have adequate porosity for 
bone repair so as to accelerate bone regeneration.  The scaffold must also replicate the 
size and shape of the defect it is going to fill.  Both of these characteristics synergistically 
play an integral role in the success of the bone substitute. And accurate repair of bone 
defects is not only important in obtaining restoration of bone function but is also 
important for cosmetic reasons as well. This is especially true for maxillofacial bone 
reconstructions. Yet many studies that have engineered biomaterials to fill irregular bone 
defects use cylinders or blocks [10, 23, 26, 31, 34].  
 
Traditional processing of biomaterials has demonstrated scaffolds with limited control 
over geometry and porosity.  These include polymer foaming technique, particulate-
leaching, solid–liquid phase separation, textile technique, and extrusion process [35]. 
These primitive methods create scaffolds which are cylinders, blocks, particles or pastes.  
The structure of these types of scaffolds does not mimic that of bone, which is essential 
to vascularization and tissue regeneration. 
 
1.3.1 Rapid Prototyping Technologies 
 
The novel technologies of solid freeform (SFF) or rapid prototyping (RP) are becoming 
the choice for scaffold processing, due to the ability to engineer scaffolds with predefined 
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and reproducible internal morphology that replicates that of natural bone. SFF 
technologies involve designing a scaffold model with 3D computer aided design (CAD) 
or obtaining data originating from computed tomography (CT) or magnetic resonance 
imaging (MRI).  This digital information can then be converted to a machine specific 
cross-sectional format, expressing the model as a series of layers.  This data is then used 
by the SFF machine which produces a physical model in a layer-by-layer method.  
Through this type of processing technology, it is possible to control scaffold architecture, 
material composition, and porosity which are all critical factors in the development and 
future success of tissue engineering. 
 
1.3.1.1 Fused Deposition Modeling  
 
Currently, there are only a few SFF techniques that are being used for scaffold 
processing.  One such RP technique that has been extensively researched is fused 
deposition modeling (FDM) [35-38]. FDM uses the concept of melt extrusion in order to 
deposit a parallel series of material roads that forms a material layer. For this type of 
scaffold fabrication, a filament material stock is fed and melted inside a heated liquefier 
head and then is extruded through a nozzle with a small orifice. For each deposited 
material layer, the direction of material deposition can be changed. By changing the 
direction of material deposition for consecutively deposited layers and the spacing 
between the material roads, scaffolds with highly uniform internal honeycomb-like 
structures, controllable pore morphology and complete pore interconnectivity are 
obtained, simulating the internal structure of bone.   
 
1.3.1.2 Selective Laser Sintering 
 
Another SFF technology that has been adapted for fabricating tissue engineering 
scaffolds is selective laser sintering (SLS) [38]. This technology utilizes a CO2 laser 
beam to selectively sinter polymer or composite powders to form material layers. The 
laser beam is directed onto a powder bed by a high precision laser scanning system. 
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Subsequent stacking and fusion of the sintered material layers creates a scaffold that 
replicates the object’s height.  Due to the powders being subjected to low compaction 
forces during their deposition to form new layers, this technology creates objects which 
are porous.  
1.3.1.3 Three-Dimensional Printing 
 
The most commonly used SFF technology is three-dimensional printing (3D-P) [38].  
This technique employs the technology of ink jet printing for the processing of materials 
in powder form. Because of the versatility and simplicity of 3D-P, it allows for the 
processing of a wide variety of biomaterials that include polymers, metals and ceramics. 
During fabrication of a scaffold, a printer head is used to print a liquid binder onto thin 
layers of selected powder.  The binder sprays an area that is the same as the scaffold’s 
cross-sectional area as generated by a system computer. The successive stacking and 
printing of material layers onto the top of previously printed layer recreates an exact 
replica of the desired object. After sintering this fabricated material, the binder is burned 
away leaving a highly porous scaffold. 
 
1.3.1.3.1 Z-Corp Processing 
 
One specific example of 3D-P called Z-Corp processing was used in this study.  A Z-
Corp 3D printer was used in order to fabricate porous disk scaffolds for in-vitro testing, 
and exact replicas of rabbit ulna segmental bone defects for in-vivo testing.  By 
combining Z-Corp processing with SCPC powder, highly porous, bioactive, resorbable 
tissue engineering scaffolds were fabricated in only minutes.  These scaffolds were 
processed with an adequate porosity for bone repair, and a specific geometry, replicating 
the size and shape of the defect it was going to fill. 
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1.4 Objectives 
 
The main goal of this study was to employ a 3D processing technique with the SCPC 
powder to develop a tissue engineering scaffold for BMP delivery and bone regeneration 
in a load bearing segmental bone defect. The specific objectives were: 
1 Evaluate the effect of different thermal treatment temperatures on the mechanical 
strength, porosity and surface area of SCPC. 
2 Evaluate the effect of thermal treatment on the dissolution kinetics of the material 
in physiological solution. 
3 Correlate the physicochemical properties of the material to the development of 
bioactive surface layer on the SCPC in physiological solution. 
4 Study the release kinetics of rh-BMP-2 from SCPC-rh-BMP-2 hybrid in 
physiological solution. 
5 Test the ability of the SCPC-rhBMP-2 hybrid to enhance bone regeneration in a 
load bearing large bone defect in the ulna of rabbit.   
Copyright © Amanda Peter Hart 2005 15
Chapter 2 
Materials and Methods 
 
2.1 In-Vitro Study 
 
2.1.1 Sample Preparation 
 
Table 2.1.1 shows the chemical compositions of the silica-calcium phosphate composite 
and hydroxyapatite (ProOsteon® 200HA) that were used in this study.  Previous studies 
in the lab have shown that the composition of ratio 75:25 Sodium Silicate to Calcium 
Phosphate has high bioactivity [33]. Batches of 100 g of the composition were placed in 
polyethylene bottles and placed on a roller mixer and allowed to mix for 24 hours to 
ensure even distribution of the powders. Each batch was moistened with 0.1% NaOH 
until a paste was formed and spread into a prefabricated teflon mold with 10 mm 
diameter × 10 mm height cylindrical cutouts. The SCPC samples were left to dry at room 
temperature and then thermally treated (Thermolyne 30400 Furnace, Sybron/Thermolyne 
Corporation, IW, USA) at 100 ˚C for 1 hour and then 800 ˚C for 1 hour.  
 
2.1.2 Z-Corp Processing 
 
Particles in the size range 45-90 µm were prepared by grinding the SCPC using a mortle 
and pestle then sieving to achieve the desired particle size range.  These particles were 
then processed using a Z-Corp 3D Printer (Z402 System, Z Corporation, Burlington, MA, 
USA).  Z-Corp printers use a powder-binder technology to create parts directly from 
digital data.  In order to get the desired shape to be modeled by the Z-Corp, the first step 
is to obtain high resolution MRI or CT data of the area of interest.  This data is then 
converted into a stereolithography (STL) data format, which remaps the surface data to a 
series of triangles that when assembled reconstruct the original geometry.  This  
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Table 2.1.1: Chemical Composition of SCPC and HA in mol % 
 
Composite code Na2O SiO2 CaO P2O5
SCPC 32.9% 32.9% 22.8% 11.4% 
HA 0 0 76.9% 23.1% 
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file is then imported into a computer aided design (CAD) software package (Amira, 
Amira 3D Professional Visualization, Berlin, Germany).  This step allows adjustments to 
the image to be made.  The final CAD image is then converted back into a STL format, 
and then into a slice file that the Z-Corp machine will use in order to replicate the model 
layer by layer.  The thickness of each of these layers can be 0.076 - 0.254 mm.  To 
process the desired prototype, first the Z-Corp spreads out a thin layer of the SCPC 
powder (Figure 2.1.2). Then, an ink-jet print head prints a water-based binder, made of 
water and agar, in the cross-section of the part being created. Next, the build piston drops 
down, making room for the next layer, and the process is repeated. Once the part is 
finished, it is surrounded and supported by loose powder, which is then shaken loose 
from the finished part.  After building the prototype, any unused powder is collected and 
can be reused.   
 
In order to make SCPC disks using the Z-Corp machine for in-vitro testing, the disks 
were first constructed in CAD software, converted to STL format and then a slice file 
which was used to process the SCPC disks using the Z-Corp machine.  Disks of size 10 
mm diameter x 10 mm height were constructed for material characterization and disks of 
size 10 mm diameter x 2 mm height were processed to study the interaction of the SCPC 
with simulated body fluid (SBF).  These disks were all processed using the Z-Corp 
machine in only minutes. 
 
2.1.3 Effect of Thermal Treatment 
 
SCPC disks were first thermally treated at a lower temperature to burn off the binder, and 
then sintered at a higher temperature to fuse the SCPC particles.  In order to determine 
the thermal treatment required to burn off the hydrocarbons from the SCPC disks, several 
different temperatures were evaluated.  SCPC disks (n=3) were treated at 300, 350, 400, 
or 450 ºC for 24 hours.  If the hydrocarbons were not completely burned away the 
samples were left with a grayish color.  The SCPC disks treated at 450 ºC were white 
after 24 hours of thermal treatment.  Next, different thermal treatment durations were  
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Figure 2.1.2: Video of Z-Corp Processing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To begin building an implant the printer head sweeps across the feed and build boxes.  
The feed box rises supplying a thin layer of SCPC powder and the printer head pushes 
that across to the build box.  Then the printer head sweeps across the build box, spraying 
a layer of the binder that is the same as the first cross-section of the part.  The feed box 
will rise by one layer height and the build box will lower by one layer.  The printer head 
will then push the next layer over to the build area creating the next layer.  This process is 
then repeated over and over until the implant is created.  The printer head will spray the 
binder, the feed box will raise, the build box will lower and the printer head will push the 
powder over creating the next layer.  Excess powder is removed and the finished implant 
is removed from the Z-Corp.  Any unused SCPC powder can then be recycled and used 
again. 
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evaluated in the same way.  SCPC disks (n=3) were thermally treated at 450 ºC for 16, 
18, 20 or 24 hours.  It was found that treating the disks at 450 ºC for 18 hours sufficiently 
burned away all the hydrocarbons from the SCPC disks. 
 
The effect of thermal treatment on the physicochemical properties of the SCPC material 
was then investigated for the sintering temperatures 800, 850, and 900 ºC.  These 
treatment temperatures allowed for the formation of interconnectivity between the pores 
of the SCPC disks.   
 
2.1.4 Material Characterization 
 
2.1.4.1 Surface Characterization 
 
To analyze the morphology of the SCPC disks, high resolution images were obtained by 
scanning electron microscope (SEM) operated at 20 kV acceleration voltage. First the 
disks were mounted on SEM stubs using colloidal graphite. The colloidal graphite was 
painted around the edges of the disks to facilitate electron conduction.  The disks were 
then gold coated under an argon atmosphere using an Emscope SC400 sputter coater.  
This was done in order to facilitate electron conduction and assist the flow of electrons on 
the surface of the SCPC disks. The samples were then loaded into the microscope 
(Hitachi S-3200, Tokyo, Japan) and analyzed in the secondary image mode (SI).  
 
2.1.4.2 Porosity Measurements 
 
The porosity percent and specific surface area of SCPC disks processed using the Z-Corp 
machine and thermally treated at 800, 850, and 900 ºC were determined with the use of 
mercury intrusion and gas adsorption techniques (Micromeretics Co., Norcros, GA).  The 
surface area of the samples was determined using the BET (Brunauer, Emmet, and 
Teller) theory.  The thermally treated samples were cooled with liquid nitrogen and 
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analyzed by measuring the volume of gas (N2) adsorbed at specific pressures.  To 
measure the porosity percent and pore size distribution, mercury intrusion porosimetry 
was used.  This technique involved placing the SCPC disks in a penetrometer, then 
surrounding the sample with mercury.  Mercury was used because it is a non-wetting 
liquid to most materials and it resists entering voids or pores, doing so only when 
pressure is applied.  The pressure applied to the mercury was increased from 0 psia to 
60,000 psia.  The pressure at which the mercury entered the pore was inversely 
proportional to the size of the pore.  
 
2.1.4.3 Mechanical Properties 
 
The compressive strength of the porous SCPC disks (10 mm diameter x 10 mm height) 
(n=5) which were subjected to various thermal treatments were evaluated using an 
Instron Machine Model 5582.  The SCPC disks were loaded uniaxially at a rate of 0.005 
in/sec until failure at room temperature.  Load and displacement were measured 
continuously by the Instron testing machine and recorded.  From this measured data, a 
stress-strain curve was derived and used to calculate ultimate compressive strength and 
failure strain of the SCPC disks.  In addition, the values for the compressive modulus 
were derived from the stress-strain curves. 
  
2.1.4.4 Evaluation of Release Kinetics of rhBMP-2 
 
2.1.4.4.1 Recombinant Human BMP-2 Preparation 
 
The recombinant human BMP-2 (rhBMP-2) used in this study was supplied by R&D 
Systems, Inc. (Minneapolis, MN). In order to reconstitute the 10 µg rhBMP-2 protein, 
300 µL of 4 mM HCl containing 0.1% BSA (albumin bovine serum) was added to the 
protein, preparing a stock solution of 1 µg per 30 µL. 
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2.1.4.4.2 Release Kinetics of rhBMP-2 
 
The SCPC implants (10 mm height x 5 mm width) (n=5) processed using the Z-Corp 3-D 
printer then thermally treated at 800, 850 or 900 ºC, and HA disks (10 mm diameter x 4 
mm height) (n=5) were placed separately in a 24-well plate and sterilized by 100% 
ethanol for 30 min and then allowed to dry.  Then the SCPC implants and HA disks were 
individually loaded with 30 µL of the reconstituted rhBMP-2.  After the rhBMP-2 was 
evenly distributed on the ceramics, they were allowed to dry for 1 h.  Next, each sample 
was individually placed in a snap cap vial and immersed in 10 mL of phosphate-buffered 
saline (PBS; pH 7.4) containing 1% BSA.  All of the samples were placed in an incubator 
at 37 ºC for a period of 14 days.  After various time periods, 1, 2, 4, and 12 hours, and 1, 
2, 4, 6, 8, 10, 12 and 14 days, 2 mL of the existing immersion PBS solution were 
exchanged with 2 mL of fresh PBS solution.  The concentration of BMP-2 released from 
the SCPC implants and the HA disks into the immersing solution was quantified with a 
Quantikine BMP-2 ELISA kit from R&D Systems, Inc. (Minneapolis, MN).  The optical 
density of each well was determined using a microplate reader set to 450 nm.  In order to 
account for wavelength correction, the optical density was also measured at 570 nm and 
subtracted from those readings done at 450 nm.   From the rhBMP-2 standard dilutions 
supplied in the ELISA kit, the optical density versus the known concentration of the 
standards was plotted and a best-fit curve was drawn. The rhBMP-2 concentration of 
each sample could be determined by finding the absorbance value on the y-axis and using 
the best-fit curve, and then finding the corresponding rhBMP-2 concentration from the x-
axis. Since after each time point the samples were diluted, the concentrations were 
multiplied by a dilution factor of 1.25 for each time point.   
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2.1.5 Study of the Interaction of SCPC with Simulated Body Fluid 
 
2.1.5.1 Preparation of Simulated Body Fluid 
 
In order to replicate that results that would occur in-vivo, the SCPC disks were immersed 
in simulated body fluid (SBF) (Table 2.1.5.1).  According to Kokubo [39], this solution 
can precisely reproduce in-vivo surface structure changes, due to its similar ion 
concentration to human blood plasma.  
 
2.1.5.2 Immersion Study 
 
SCPC disks (10 mm diameter x 2 mm height), pre-treated at different temperatures, were 
placed in 6-well plates and immersed in 6 ml SBF for 12 hours, 1, 3, or 5 days.  The 
plates were incubated at 37 ºC for the duration of the immersion time.  At the end of each 
time period, the disks were removed from the SBF, rinsed with deionized water, dried at 
room temperature and used for surface analyses. The immersion SBF solution was 
dispensed into 15 ml centrifuge tubes and stored in a freezer for the analysis of SCPC 
dissolution kinetics. 
 
2.1.5.3 SCPC Dissolution Kinetics 
 
After immersion of the SCPC disks, the SBF ionic concentrations were analyzed by 
inductively coupled plasma-optical emission spectrometry (ICP-OES) (Perkin Elmer 
Optima 2000 DV, Wellesley, MA, USA).  To analyze the concentrations of Ca, P, and Si, 
the collected SBF was diluted 3 times.  To analyze the Na concentration, the SBF was 
diluted 36 times. These dilutions were necessary due to the ionic concentrations of the 
SBF being too high to be quantified by the machine. As a washing solution, 0.01% Triton 
X was prepared. Diluted SBF samples were placed in the autosampler tray along with the 
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Table 2.1.5.1:  Simulated Body Fluid Concentrations 
 
 Concentrations (mM) 
Na+ 142.0 
K+ 5.0 
Mg2+ 1.5 
Ca2+ 2.5 
Cl- 148.8 
HCO3- 4.2 
HPO42- 1.0 
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standards of Ca, P, Si, and Na.  The samples were then fed into the plasma.  Atoms in the 
plasma emit photons with characteristic wavelengths for each element being analyzed.  
This photon emission is recorded by an optical spectrometer and when calibrated against 
the standards, this technique provided a quantitative analysis of the ionic concentrations 
of the SBF samples.  
 
2.1.5.4 Surface Chemistry Analysis 
 
To analyze modifications in the surface chemistry during immersion in SBF, the 
functional groups on the surface of the SCPC disks, before and after immersion in SBF, 
were analyzed by Fourier Transform Infrared Spectroscopy (FTIR) (Thermo Nicolet 
Nexus 670 FT-IR, Madison, WI, USA).  The disks were analyzed in the diffuse 
reflectance mode in the wave number range of 400–4000 cm−1.  The spectra of the 
immersed SCPC disks were compared to the spectra of SCPC before immersion in SBF. 
A spectrum for KBr was used as a background.   
 
2.1.5.5 Surface Modification 
 
To analyze the morphology of the SCPC disks after immersion in SBF, images were 
obtained by SEM as previously described.  
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2.2 In-Vivo Study 
 
2.2.1 Experimental Setup 
 
2.2.1.1 General Experimental Protocol 
 
Nine male New Zealand White Rabbits (3 kg, Myrtle's Rabbitry, Thompson Station, TN, 
USA) were used to evaluate tissue response to the SCPC implant. The rabbit ulna was 
subjected to CT scan and the CT file was used with a Z-Corp machine to make a bone 
prototype employing SCPC powder. To induce osteoinduction, the SCPC implant was 
loaded with 10 µg of rhBMP-2.  rhBMP-2 was used because of its significant role in 
inducing bone cell differentiation, which is well documented in the literature [1, 2, 7-9, 
23, 24]. Surgical procedures were performed to remove a 10 mm segment of the ulna and 
then the defect was grafted with the SCPC-rhBMP-2 hybrid. Plates and screws were used 
to provide initial fixation. After 12 or 16 weeks the animals were euthanized. The 
morphology and mechanical strength of the regenerated bone were analyzed.  
 
2.2.1.2 Prototype Processing 
 
Prior to surgery, the rabbits had CT scans (Siemens Somatom Plus 4, Siemens Somatom 
Sensation 10, Erlangen, Germany) performed on their right forearms.  For the CT scans 
the rabbits were anesthetized with 10 mg/kg xylazine subcutaneously and 50 mg/kg 
ketamine intramuscularly.  The CT data was then converted into STL format, which 
remapped the surface data to a series of triangles.  These images were then imported into 
the Amira CAD software where adjustments could be made (Figures 2.2.1.2 (a-b)).  
Using the CAD software, the ulna was isolated from the radius. Then a 10 mm bone 
segment was removed in the image; 20 mm proximal to the styloid process (Figure 
2.2.1.2 (c-e)). The final CAD image of the defect was then converted back into a STL  
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a 
 
 
Figure 2.2.1.2 (a-e): Z-Corp Processing 
These images are of the CT scan data that has been converted into a CAD file.  Figure 
2.2.1.2 (a) shows the rabbit legs as they would normally appear. 
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b 
 
Figure 2.2.1.2 (a-e):  Z-Corp Processing (continued) 
These images are of the CT scan data that has been converted into a CAD file.    Figure 
2.2.1.2 (b) shows the same image as Figure 2.2.1.2 (a) but with the outer layers removed 
so that only the bones can be seen.  All of this is done using Amira CAD software.  From 
here the ulna can be isolated. 
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c 
 
Figure 2.2.1.2 (a-e): Z-Corp Processing (continued) 
These images show the isolated ulna in the CAD software.  Figure 2.2.1.2 (c) shows the 
10 mm segment to be sectioned out of the ulna 20 mm proximal to the styloid process.  
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Figure 2.2.1.2 (a-e): Z-Corp Processing (continued) 
These images show the isolated ulna in the CAD software. Figure 2.2.1.2 (d) shows the 
ulna with the segment removed. 
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e 
 
 
Figure 2.2.1.2 (a-e): Z-Corp Processing (continued) 
These images show the isolated ulna in the CAD software.  Figure 2.2.1.2 (e) is an 
enlarged image of the 10 mm segmental defect to be replicated using the SCPC powder 
and fabricated using the Z-Corp processing RP technique.  It can be seen that the 
geometry and topography of the defect is complicated. 
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format, and then into a slice file that the Z-Corp machine used to replicate the removed 
bone segment layer by layer.  To synthesize the desired implant, the Z-Corp spread out a 
thin layer of the SCPC powder, then the ink-jet printer head printed a water-based binder 
in the cross-section of the implant being created. The build piston which had the SCPC 
powder then would drop down, making room for the next layer, and the process was 
repeated until an implant that exactly replicated the removed bone segment had been 
processed.  
 
2.2.1.3 Thermal Treatment 
 
The implants processed by the Z-Corp were heat treated at 450 ºC for 18 hours to burn 
off the binder used to secure the layers and any other hydrocarbons and then at 800, 850 
or 900 ºC for 3 hours to sinter the SCPC implants. 
  
2.2.1.4 Sterilization 
 
Prior to surgery, the implants were sterilized by immersing them in 70% ethanol for 30 
minutes under a sterile hood.  Tweezers, used for handling the implants, were also 
immersed in ethanol.  After sterilization, the implants were placed in sterile cell culture 
dishes to dry. 
 
2.2.1.5 Construct of SCPC-rhBMP-2 Scaffold  
 
In order to reconstitute the rhBMP-2, 40 µl of 4mM HCl containing 0.1% BSA was 
sterilized by filtering through a 45 µm pore opening and then dispensed into a vial 
containing 10 µg of rhBMP-2.  The BSA was added to prevent loss in activity caused by 
non-specific binding of BMP to the inside surface of the vial. The BMP solution was 
immediately dispensed evenly on all sides of the sterilized SCPC implant.   
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2.2.1.6 Surgery 
 
Rabbits were anesthetized with an intravenous injection of 10 mg/kg xylazine followed 
by 50 mg/kg ketamine. The right forearm was shaved and the skin was sterilized with 
povidone-iodine and draped with sterile towels.  Under aseptic conditions, the right ulna 
was exposed through a straight incision of approximately 3 cm long.  The ulna was 
separated from the surrounding muscles and the periosteum was cut through to expose 
the ulna bone.  A critical sized segmental defect was then created in the ulna of the right 
forelimb by removing 10 mm of midshaft diaphyseal bone 20 mm proximal to the styloid 
process. 
 
The SCPC implant, thermal treated at 800 (n=1), 850 (n=2) or 900 ºC (n=6), was placed 
in the defect.  The implant, made individually for each rabbit using the Z-Corp machine, 
was secured in place using plate and screws.  Using Vicryl, the incision was closed 
subcutaneously layer by layer, to prevent the rabbit from chewing out any sutures.  Then 
skin glue was placed over the outside of the incision.  The rabbits received 0.05 mg/kg 
buprenorphine 30 minutes prior to the end of surgery and then every 8 to 12 hours as 
needed for pain.  After recovery, the rabbits were allowed to be load bearing without 
external support on the leg.  
Two rabbits died prior to surgery, during anesthetizing, due to unknown complications.  
These rabbits were to have received SCPC implants thermally treated at 850 ºC. 
 
2.2.2 Evaluation of SCPC-rhBMP-2 Graft 
 
2.2.2.1 Radiographic Evaluation 
 
In order to evaluate bone formation, union and remodeling of the defect, CT scans were 
performed postoperatively at 4, 8, and 12 weeks. The CT scans were performed at 64 
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slices per rotation with an isotrope CT resolution of 0.4 mm.  The high resolution CT data 
was then converted into STL data format, remapping the surface data into a series of 
triangles, and then imported into a CAD file.  This allowed for a non-invasive 3-D view 
of the remodeled defect.  
 
2.2.2.2 Histology 
 
The ulna treated with an 800 ºC thermally treated SCPC-rhBMP-2 hybrid implant was 
harvested from a rabbit that was euthanized by an overdose of sodium pentobarbital 16 
weeks post-operatively.  This ulna was used for non-decalcified histological evaluation.  
The bone specimen was fixed in 10% buffered formalin solution and then embedded in 
polyethlymethacrylate (PMMA), and the non-decalcified sections (40 µm) were ground 
and prepared using an Exakt machine (Exakt Technologies, Inc., Oklahoma City, OK).  
The sections were made along the long axis of the ulna and were stained with Toluidine 
Blue and examined for histological evaluation. 
 
2.2.2.3 Torsional Testing 
 
In order to assess the mechanical properties of the rabbit ulna, the ulna was subjected to 
torsional testing.  Each rabbit treated with a 900 ºC thermally treated SCPC-rhBMP-2 
hybrid implant was euthanized at 12 weeks postoperatively.  Both ulnae (grafted (n=3) 
and ungrafted (n=3)) from each rabbit were harvested, cleaned of soft tissue and used for 
mechanical testing.  Specimens with insufficient bone healing (n=3), due to failure of the 
fixation device, were excluded from torsional testing.  The fixation devices on those 
ulnae with sufficient healing were carefully removed. Care was taken to ensure that no 
excessive mechanical loads were applied to these ulnae during the harvesting process.  
Each harvested ulna was then immediately wrapped in gauze moistened with Ringers 
solution, sealed in a labeled storage bag, and then fresh frozen at -20 ºC until testing. 
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All ulnae to be mechanically tested were defrosted by removing them from the freezer 
and storing them in a refrigerator at 2 °C for 24 hours prior to testing, while still wrapped 
with gauze moistened with Ringers solution. Then the ulnae were removed from the 
sealed storage bag and prepared for testing by trimming the grafted ulna with a slow 
speed diamond wafer saw blade subjected to constant irrigation at sites 2 cm proximal 
and distal from the proximal and distal defect ends, so that the total length of the testing 
sample was 5 cm. The ungrafted ulna was also isolated and trimmed at the corresponding 
sites so it too had a length of 5 cm. 
 
Once the ulnae were at the appropriate length, both ends of the bone were inserted into a 
custom-made alignment fixture, and 1 cm of each end of the ulna was potted in JB Weld.    
This custom made alignment fixture was used to ensure that the longitudinal axis of the 
bone was parallel and concentric with the torsional testing axis.  It also ensured that the 
gauge length (the total length of the ulna unpotted) was consistent to ±1 mm, and this 
amount was measured by using a pair of digital outside vernier calipers accurate to 0.01 
mm.  During the healing of the bone defect, bony fusion had occurred between the ulna 
and the radius.  Separation of the radius from the ulna was not possible due to the fibrous 
fusion. All limbs were kept physiologically moist by keeping the gauze moistened with 
Ringers solution continually wrapped around the ulnae throughout the potting and testing 
procedures.   
 
After approximately 24 hours of room temperature hardening, the potted specimens were 
mounted in a custom built torsional testing fixture which was secured to a computer-
controlled, biaxial servo-hydraulic material testing system (Instron 8521, Canton, MA, 
USA).  Mechanical testing to failure was performed at room temperature. With the 
proximal end held fixed, the distal end was externally rotated at a constant rate of 90 
°min−1 until failure.  For those specimens with no clear failure, the maximum rotation and 
energy to failure was computed for a displacement up to 35 º. Torque versus angular 
deformation curves were obtained by using the accompanying Instron System 8800 
Controller.  Maximum torsional load to failure and angle at failure were measured.  
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After the specimens had catastrophically failed, the cross-sectional areas of the ulnae 
were obtained by sectioning with a diamond wafer saw blade subjected to continuous 
irrigation.  These cross-sections were photographed, and the cross-sectional areas were 
calculated by using image analysis freeware (NIH Image 1.59, Bethesda, MD, USA).  
The calculated cross-sectional area data, along with the gauge length and other measured 
torsional test data were then used to calculate the values of maximum torsional load to 
failure and torsional angle at failure for grafted and control ungrafted bone.  All broken 
torsional testing specimens were properly labeled with an indelible ink marker and 
returned to their marked storage bags, and then refrozen in the event that additional study 
was needed.  
  
2.3 Statistical Analysis 
 
Representative values of parameters used in this study were shown as mean ± standard 
deviation.  Each parameter was statistically analyzed by a t-test with two samples 
assuming unequal variances.  A p-value of less than 0.05 was considered to be 
statistically significant. 
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Chapter 3 
Results 
 
3.1 Material Characterization 
 
3.1.1 Morphology Analysis  
 
SEM of the SCPC disks processed using the Z-Corp machine and thermally treated at 
800, 850, and 900 ºC showed the disks to be highly porous with interconnected pathways 
between the pores (Figure 3.1.1 (a-d)). For all thermal treatment temperatures at high 
magnification, a porous structure containing micropores of size range 20-100µm is 
visible and the interconnections between these pores are in the range of 10 - 50 µm.  
Figure 3.1.1 (a) shows two large micropores that are surrounded by interconnected 
pathways in a disk treated at 800 ºC.  Figure 3.1.1 (b) shows that the disk treated at 850 
ºC has a similar structure of micropores and interconnections.  Figure 4.1.1 (c) shows that 
pores on the SCPC disk thermally treated at 900 ºC has smoother edges and are more 
defined.  The micrographs show that as the thermal treatment temperature of the SCPC 
disks is increased the particle edges become smoother showing a greater level of 
interconnectivity between the pores.  Moreover, at a higher magnification, it can be seen 
that the surface of the SCPC disks are covered by nanopores (Figure 3.1.1 (d)).   
 
3.1.2 Porosity Measurements 
 
Table 3.1.2 summarizes the results from the porosity and surface area analysis.  The 
analysis of the porosity shows that the porosity is greatest for the SCPC disks thermally 
treated at 800 ºC with a porosity percent of 54%, then 50% at 850 ºC, and then 900 ºC 
had the porosity percent of 44%.  The surface area of the thermally treated SCPC disks 
also was greatest for the lower sintering temperature.  The disks treated at 800 ºC had a  
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a 
 
 
Figure 3.1.1 (a-d): SEM Micrographs Before Immersion 
SEM micrographs of SCPC disks show that the particle edges become smoother as the 
thermal treatment temperature is increased. (a) Two large micropores (dashed lines) of 
the disks treated at 800 ºC are surrounded by interconnected pathways of smaller pores 
(arrows).   
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b 
 
Figure 3.1.1 (a-d): SEM Micrographs Before Immersion (continued) 
SEM micrographs of SCPC disks show that the particle edges become smoother as the 
thermal treatment temperature is increased. (b) Disks treated at 850 ºC show a similar 
structure of micropores (dashed lines) and smaller interconnected pores (arrows). 
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c 
 
Figure 3.1.1 (a-d): SEM Micrographs Before Immersion (continued) 
SEM micrographs of SCPC disks show that the particle edges become smoother as the 
thermal treatment temperature is increased. (c) Disks treated at 900 ºC show more 
defined micropores (dashed lines) and interconnection (arrows) with smoother edges.  
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d 
 
Figure 3.1.1 (a-d): SEM Micrographs Before Immersion (continued) 
SEM micrographs of SCPC disks show that the particle edges become smoother as the 
thermal treatment temperature is increased. (d) High magnification of the disks  treated at 
850 ºC reveal that the disks are not only microporous, but the surface is also covered with 
nanopores (arrows), providing for a large surface area for drug delivery.   
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Table 3.1.2:  Porosity Analysis 
 
Porosity analysis shows that the porosity percent and surface area were dependent on the 
thermal treatment of the SCPC disks.  As the thermal treatment temperature was 
increased the porosity percent and surface area both decreased.  
 
 
Pore Size Distribution % 
 
As determined by BET and 
Hg intrusion 
 
Treatment 
Temperature 
 
356-100 
µm 
 
100-25 
µm 
 
25-10 
µm 
 
10-1 
µm 
 
1 µm-
4 nm 
 
Surface Area 
(m2/g) 
 
Porosity 
% 
800 ºC 3.00 22.86 48.76 22.42 2.96 3.442 54 
850 ºC 2.71 7.12 70.71 17.88 1.57 2.814 50 
900 ºC 4.74 12.73 60.36 19.69 2.48 2.615 44 
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surface area of 3.442 m2/g, then 2.814 m2/g at 850 ºC, and those treated at 900 ºC had a 
surface area of 2.615 m2/g.  As for the pore size distribution, the thermal treatment 
temperature had no effect on the distribution of pores greater than 100 µm or less than 10  
µm.  However, for the SCPC disks treated at 800 ºC, 48.76% of the pores were in the 
range of 25 µm-10 µm while 22.86% were in the range of 100 µm-25 µm. When the 
thermal treatment was changed to 850 ºC, the percent of pores in the range of 25 µm-10 
µm jumped up to 70.71% and the percent dropped to 7.12% in the 100 µm-25 µm range.  
For the disks treated at 900 ºC, the percent of pores in the range of 25 µm-10 µm 
decreased down to 60.36% and the percent of pores in the range of 100 µm-25 µm 
increased to 12.73%.  
 
3.1.3 Mechanical Testing 
 
The mechanical properties of the SCPC disks were dependent on the thermal treatment 
temperature (Table 3.1.3).  The compressive strengths and modulus of the disks 
significantly increase with the increase of the thermal treatment temperature (n=5, 
p<0.04).  The ultimate compressive strength and the compressive modulus of the disks 
range from 5-15 MPa and 300 MPa-1.1 GPa, respectively.  The disks treated at 900 ºC 
have a significantly higher compressive strength and modulus as compared to those disks 
treated at 800 ºC (p<0.003) and 850 ºC (p<0.003).   Moreover, the disks treated at 850 ºC 
have a significantly higher compressive strength and compressive modulus as compared 
to the disks treated at 800 ºC, p<0.008 and p<0.0006, respectively.  These results are 
consistent with the SEM results showing that as the thermal treatment temperature 
increased, there is greater interconnectivity between the SCPC particles, and thus greater 
mechanical strength.  Conversely, as the porosity percent of the SCPC disks is increased 
the mechanical strengths decrease.  
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Table 3.1.3:  Mechanical Properties Results 
 
Mechanical properties of the SCPC disks after thermal treatment indicate that the 
ultimate compressive strength and the compressive modulus of the disks increased as the 
thermal treatment temperature increased.  The ultimate compressive strength of the disks 
(5-15 MPa) is comparable to that of trabecular bone (2-12 MPa). However, as the 
porosity percent increased (Table 3.1.2) the mechanical strength decreased. 
 
Treatment 
Temperature 
Ultimate 
Compressive 
Strength 
Failure Strain 
Compressive 
Modulus 
800 ºC 5.584 ± 0.52 MPa 0.0198 ± 0.003 307 ± 44MPa 
850 ºC 8.977 ± 1.60 MPa 0.0164 ± 0.002 551± 56 MPa 
900 ºC 15.326 ± 2.95 MPa 0.0138 ± 0.005 1095 ± 164 MPa 
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3.1.4 Release Kinetics of rhBMP-2 
 
Analysis of the release kinetics of rhBMP-2 from the SCPC-rhBMP-2 hybrid and the 
HA-rhBMP-2 hybrid showed that after 2 days the concentration of rhBMP-2 released was 
not significantly different between the two (Figure 3.1.4).  However, after 2 days, the 
amount of rhBMP-2 released from the SCPC-rhBMP-2 hybrid is significantly greater 
(p<0.04), than that of the HA-rhBMP-2 hybrid.  At 14 days the concentrations of rhBMP-
2 is not significantly different between the two hybrids.  
 
3.2 Interaction of SCPC with SBF 
 
3.2.1 ICP 
 
ICP analyses of the ionic concentrations of SBF for calcium (Ca), phosphorus (P), silicon 
(Si) and sodium (Na) after immersing thermally treated SCPC disks in the SBF are shown 
in Figure 3.2.1 (a-d).  Analysis shows that the Ca concentration of the SBF incubated 
with all SCPC disks drops drastically after the first 12 hours of immersion (Figure 3.2.1 
(a)).  Moreover, thermal treatment has a profound effect on the corrosion behavior of the 
material.  The Ca concentration of SBF incubated with SCPC treated at 800 ºC is 
significantly (n=3, p<0.03) higher than the Ca concentration of SBF incubated with 
SCPC treated at 850 and 900 ºC.  However, the difference in Ca concentration of the SBF 
incubated with SCPC treated at 850 or 900 ºC is not significantly different. After 12 
hours, the Ca concentration of the SBF decreases according to the temperature of the 
treatment of the ceramic in the order 800 ºC > 850 ºC > 900 ºC.  Similar concentrations 
of Ca are measured in the immersion solution after 12 hours, and 1, 3, and 5 days for all 
disks which indicates equilibrium between the dissolution and precipitation reactions at 
the material-solution interface.   
  
In contrary to the immediate decrease in the Ca concentration, the P concentration 
significantly increases after the first 12 hours and then after 1 day begins to slope down  
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Figure 3.1.4:  Cumulative Release of rhBMP-2 from SCPC and HA 
The graph of the cumulative release of rhBMP-2 from the SCPC implant and the HA disk 
shows that the release from the SCPC implant is greater than that from the HA disk.  This 
release was significantly more (p<0.04) from 4-12 days. 
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a 
Figure 3.2.1 (a-d): ICP Results 
ICP results show the ionic concentrations of SBF incubated at 37 ºC with thermally 
treated SCPC disks.  (a) The Ca concentration of SBF decreased due to the precipitation 
of a HA layer onto the SCPC surface.  
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Figure 3.2.1 (a-d):  ICP Results (continued) 
ICP results show the ionic concentrations of SBF incubated at 37 ºC with thermally 
treated SCPC disks. (b) In contrary to the Ca decrease, the P concentration of SBF 
increased due to not all P ions dissolving from the material being consumed in the 
formation of a HA surface layer.   
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c 
Figure 3.2.1 (a-d):  ICP Results (continued) 
ICP results show the ionic concentrations of SBF incubated at 37 ºC with thermally 
treated SCPC disks. (c) The Si concentration increased as the immersion time increased.  
This was due to its dissolution from the SCPC disk into the SBF, allowing for the 
nucleation of a HA layer apart form the SCPC disk.   
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Figure 3.2.1 (a-d):  ICP Results (continued) 
ICP results show the ionic concentrations of SBF incubated at 37 ºC with thermally 
treated SCPC disks. (d) The Na concentration of the SBF increased as the immersion 
time increased.  As the SCPC disk was immersed, there was dissolution of Na from the 
SCPC into the SBF. 
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and plateau out (Figure 3.2.1 (b)).  The ICP results also show that the thermal treatment 
temperature has a significant effect on the corrosion of P.  After  12 hours of immersion, 
the P concentration of the SBF decreases according to the thermal treatment temperature 
of the ceramic in the order 850 ºC > 800 ºC > 900 ºC.  The SBF incubated with SCPC 
disks thermally treated at 850 ºC has a significantly higher (n=3, p<0.02) P concentration 
than the P concentration of SBF incubated with SCPC treated at 850 ºC, which is in turn  
significantly higher (n=3, p<0.01) than the P concentration of SBF incubated with SCPC 
treated at 900 ºC.  Even with these significant differences, they all follow the same trend 
of significantly increasing after the first 12 hours and then after 1 day through the rest of 
the immersion time begin to plateau out.  This plateau shows that the P concentrations of 
the SBF are reaching the equilibrium state in the same way that the Ca concentrations are, 
and for the same reason.   
    
The Si concentration of the SBF exhibits a significant linear increase for the duration of 
the immersion times (Figure 3.2.1 (c)).  After all immersion times, the Si concentration of 
the SBF incubated with SCPC disks shows that the thermal treatment has a major impact 
on the corrosion behavior of the SCPC disks. The Si corrosion increased according to the 
thermal treatment temperature of the ceramic before immersion in the order 850 ºC > 800 
ºC > 900 ºC.  The SBF incubated with SCPC disks thermally treated at 850 ºC has a 
significantly  higher (n=3, p<0.03) Si concentration than the Si concentration of SBF 
incubated with SCPC treated at 800 ºC, which in turn is also significantly higher (n=3, 
p<0.03) than the Si concentration of SBF incubated with SCPC treated at 900 ºC.  
Nevertheless, even with these significant differences, they all follow the trend of 
increasing linearly through 3 days of immersion.  After 3 days, the Si concentration of the 
SBF incubated with SCPC thermally treated at 800 and 850 ºC begins to show signs of 
leveling off.  Conversely, the Si concentration of the SBF incubated with SCPC treated at 
900 ºC continues to increase.  
 
The concentration of Na of the SBF also increases gradually as the immersion duration 
progresses (Figure 3.2.1 (d)).  For the Na concentrations, the thermal treatment 
temperature of the SCPC disks has little effect on their corrosion, showing no significant 
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differences in the concentrations.  The Na concentration of the SBF incubated with the 
thermally treated SCPC disks increases from the initial concentration to 12 hours of 
immersion and then begins to plateau out after 12 hours of immersion.  The concentration 
of the SBF incubated with the disks treated at 800 and 900 ºC continues to level off after 
3 days of immersion and then begins to increase again.  The Na concentration of the SBF 
incubated with the disks treated at 850 ºC also begins to level off after 12 hours of 
immersion, but unlike the other thermal treatment temperatures, begins to increase again 
after 1 day of immersion.  Even so, these differences are no statically significant, so the 
thermal treatment of the SCPC disks does not affect the Na concentration of the SBF that 
they are immersed in.  
 
3.2.2 FTIR 
 
Prior to immersing the SCPC disks in SBF, FTIR spectra of the SCPC surface at all 
thermal treatment temperatures demonstrate similar function groups, including distinct Si 
signals (Figure 3.2.2 (a-c)).  These signals include the Si─O bending mode at 520 cm-1 
and S─O vibrational stretch at 1098 cm-1.  The peak at 848 cm-1 is a result of the P─OH 
stretching mode of HPO4.  Peaks that are characteristic for the bending vibrational modes 
of P─O are demonstrated at 568, 611, and 1052 cm-1.  The shoulder peak at 925 cm-1 is 
due to Si ─O-+Na bonds that occur in the SCPC composite.  
 
After 12 hours of immersion in SBF, FTIR spectra for the different thermal treatment 
temperatures of SCPC disks demonstrate altered surface functional groups.  The 
immersion in SBF causes the development of a new peak for C─O vibrational mode of 
carbonate at 860 cm-1. Peaks for P─O, characteristic of carbonate hydroxyapatite, are 
observed at 565, 605, and 1035 cm-1. As the presence of new peaks demonstrates the 
formation of a hydroxyapatite layer on the surface of the SCPC disks, the peaks 
characteristic for Si─O-+Na and Si─O vibrational stretch become less prominent.  
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a 
Figure 3.2.2 (a-c): FTIR Results 
FTIR results show that after 12 hours of immersion in SBF, the surface of the SCPC 
disks was altered similarly for all three thermal treatment temperatures.  Characteristics 
of a HA later are noted by the P─O peaks at 568 and 1052 cm-1, and the shoulder at 605 
cm-1. In addition, the Si─O peaks decreased on the surface of the SCPC disks which 
correlates with the ICP results (Figure 3.2.1 (c)).  (a) Disks thermally treated at 800 ºC.  
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c 
Figure 3.2.2 (a-c):  FTIR Results (continued) 
FTIR results show that after 12 hours of immersion in SBF, the surface of the SCPC 
disks was altered similarly for all three thermal treatment temperatures. (b) Disks 
thermally treated at 850 ºC. (c) Disks thermally treated at 900 ºC.    
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3.2.3 Surface Modification 
 
The SEM micrographs in Figure 3.2.3 (a-c) confirms the formation of a HA layer on all 
SCPC disks after 12 hours of immersion in SBF.  The SEM micrograph (Figure 3.2.3 (a)) 
of the SCPC disk treated at 800 ºC shows a HA layer that is in its early stages of 
development.  The apatite crystals are dense but they are small.  This correlates with the  
FTIR spectra that show P─O peaks that are characteristic of HA formation but that are 
not strong peaks.  The micrograph (Figure 3.2.3 (b)) shows that the apatite formation on 
the surface of the SCPC disk thermally treated at 850 ºC is denser and more developed 
than the other thermal treatment temperatures.  The surface of the SCPC disk is not 
visible through the apatite formation.  The FTIR spectra shows the P─O shoulder at 605 
cm-1 to be more defined for the SCPC disk thermally treated at 850 ºC, which 
distinguishes the apatite layer seen in Figure 3.2.3 (b).  For the 900 ºC disk, the HA 
crystals are large (Figure 3.2.3 (c)), but the surface of the SCPC disk can be seen.  Again, 
the FTIR spectra confirmed the formation of the HA layer on the surface of the SCPC 
disk thermally treated at 900 ºC. 
 
After 1 day of immersion in SBF, the SEM micrographs (Figure 3.2.3 (d-f)) show HA 
layers that are more developed and that fully cover the surfaces of the thermally treated 
SCPC disks.  The formation of the HA layer is confirmed by FTIR results (Figure 3.2.2 
(a-c)) and correlates well with the significant decrease in the Ca concentration of the SBF 
during immersion.  
 
3.3 SCPC-rhBMP-2 Hybrid Implantation 
 
3.3.1 Radiographs 
 
Data from a CT scan that was performed 4 weeks postoperatively on the rabbit ulna that 
was implanted with an 850 ºC thermally treated SCPC-rhBMP-2 hybrid, was converted 
into STL format allowing for a 3-D view of the bone.  Figure 3.3.1 (a-b) shows that over  
65% of the critical sized defect, initially 10 mm long, has been replaced by newly formed 
bone.  The CT scan images show the significant bone healing and regeneration, as well as  
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a 
Figure 3.2.3 (a-f): SEM Micrographs After Immersion 
SEM micrographs of the SCPC disk surface show that for all thermal treatment 
temperatures a HA layer had formed after only 12 hours of immersion in SBF.  After 24 
hours of immersion, these layers became denser.  (a) Disks treated at 800 ºC show a 
dense layer of small apatite crystals (2 µm) after 12 hours of immersion. 
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b 
Figure 3.2.3 (a-f): SEM Micrographs After Immersion (continued) 
SEM micrographs of the SCPC disk surface show that for all thermal treatment 
temperatures a HA layer had formed after only 12 hours of immersion in SBF.  After 24 
hours of immersion, these layers became denser. (b) Disks treated at 850 ºC show larger 
apatite crystals (5 µm) that cover the surface.   
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c 
 
Figure 3.2.3 (a-f):  SEM Micrographs After Immersion (continued) 
SEM micrographs of the SCPC disk surface show that for all thermal treatment 
temperatures a HA layer had formed after only 12 hours of immersion in SBF.  After 24 
hours of immersion, these layers became denser.  (c) Large apatite crystals (5 µm) are 
less dense on the disks treated at 900 ºC.  
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d 
 
Figure 3.2.3 (a-f):  SEM Micrographs After Immersion (continued) 
SEM micrographs of the SCPC disk surface show that for all thermal treatment 
temperatures a HA layer had formed after only 12 hours of immersion in SBF.  After 24 
hours of immersion, these layers became denser. (d) After 24 hours of immersion, the 
800 ºC disks a more dense formation of the smaller apatite crystals. 
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e 
 
Figure 3.2.3 (a-f):  SEM Micrographs After Immersion (continued) 
SEM micrographs of the SCPC disk surface show that for all thermal treatment 
temperatures a HA layer had formed after only 12 hours of immersion in SBF.  After 24 
hours of immersion, these layers became denser.  (e) The disks treated at 850 ºC have a 
thick apatite layer consisting of large apatite crystals. 
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f 
 
Figure 3.2.3 (a-f):  SEM Micrographs After Immersion (continued) 
SEM micrographs of the SCPC disk surface show that for all thermal treatment 
temperatures a HA layer had formed after only 12 hours of immersion in SBF.  After 24 
hours of immersion, these layers became denser.  (f) The large apatite crystals cover more 
of the surface, but the SCPC material can still be seen through the hydroxyapatite layer. 
These results are consistent with the ICP and FTIR results (Figure 3.2.1 (a-d) and 3.2.2 
(a-c)). 
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Figure 3.3.1 (a-d): Radiographic Evaluation 
Initially a 10 mm long segmental defect was created in the ulna. (a) The dashed lines 
refer to the original edges of the defect, and the arrows point to the plate that was used to 
provide the initial support in the leg.  Approximately 65% of the implant has been 
replaced by regenerated bone. (b)  This shows the healing on the other side of the ulna 
defect.  The black circles represent the place of the screws inserted into the plate to 
provide initial fixation and stability. 
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c 
 
Figure 3.3.1 (a-d):  Radiographic Evaluation (continued) 
Digital images were taken of the rabbit ulna grafted with the SCPC-rhBMP-2 hybrid 
implant 16 weeks post-operative. (c)  This image shows the superior side of the ulna and 
radius which have become fused during the healing of the 10 mm defect (dashed lines 
refer to the original edges defect).  The implant can barely be distinguished from the bone 
due to the abundant formation of new bone.  In this regenerated bone the high 
vascularization can be seen. 
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d 
 
Figure 3.3.1 (c-d):  Radiographic Evaluation (continued) 
Digital images were taken of the rabbit ulna grafted with the SCPC-rhBMP-2 hybrid 
implant 16 weeks post-operative. (d) Exceptional healing on the inferior side of the ulna 
can also be seen.  After 16 weeks the resorbable implant shows near complete healing of 
the defect.  These images confirm the in-vitro results that showed the SCPC implant to be 
both bioactive and resorbable. 
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full implant integration, all which can be observed non-invasively during the healing 
process.    
 
After 16 weeks post-operative, the rabbit was euthanized and the ulna was harvested and 
the surrounding tissue was removed.  Digital images of the superior and inferior sides of 
the ulna show almost complete healing of the 10 mm critical sized segmental defect 
(Figure 3.3.1 (c-d)).  Figure 3.3.1 (c) also shows the large amount of vascularization 
taking place in side the new bone formation. 
 
3.3.2 Histology 
 
After 16 weeks of implantation, the segmental defect in the rabbit ulna implanted with 
the 800 ºC thermally treated SCPC-rhBMP-2 hybrid was filled with mature bone and 
osteocytes.  Histological analysis of the grafted ulna shows abundant bone formation, and 
bony bridging of the defect can be observed (Figure 3.3.2 (a-b)).  Some remnants of the 
SCPC biomaterial are present, with bone formation directly on their surface.  In general, 
these remnants are incorporated in newly formed bone, and no inflammatory reactions 
could be detected.  The mature bone is also highly vascularized evident by the numerous 
blood vessels filled with red blood cells.  In addition, osteoblasts can be seen actively 
forming new bone.   
 
3.3.3 Torsional Testing 
 
Table 3.3.3 is a summary of the torsional testing results comparing the ulna implanted 
with a 900 ºC thermally treated SCPC-rhBMP-2 graft to the ungrafted rabbit ulna. The 
mechanical testing of the ulna grafted with the SCPC-rhBMP-2 hybrid (n=3) as 
compared to the control ulna with no graft (n=3) shows that the maximum torsional load 
to failure is significantly higher (p<0.04) for the ulna grafted with the SCPC-rhBMP-2 
hybrid.  In comparing the angle at failure there is not a significant difference between the 
grafted and ungrafted ulna.  These results are normalized for the cross-sectional area 
which is greater for the grafted ulna which has fused with the radius. 
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a 
 
Figure 3.3.2 (a-b): Histological Analysis 
Histological analysis of the rabbit ulna after 16 weeks of implantation showed that the 
SCPC-rhBMP-2 implant had been replaced by regenerated mature bone.  (a)  This image 
shows that the regenerated bone is highly vascularized. Black arrows point to the blood 
vessels containing red blood cells indicating vascularization of the regenerated bone 
tissue.  In addition, osteocytes (red arrows) can be seen in the mature mineralized tissue.  
Remnants of the SCPC material (white arrows) are incorporated in the newly formed 
bone and osteoblasts (yellow arrows) can be seen actively forming new bone.  
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b 
 
 
Figure 3.3.2 (a-b):  Histological Analysis (continued) 
Histological analysis of the rabbit ulna after 12 weeks of implantation showed that the 
SCPC-rhBMP-2 implant had been replaced by regenerated mature bone.  (b) A closer 
look shows the large number of red blood cells (white arrows) in the regenerated bone.
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Table 3.3.3:  Torsional Testing Results 
Torsional testing of the ulna grafted with the SCPC-rhBMP-2 hybrid and the ungrafted 
ulna showed that the maximum torsional load to failure was significantly greater (p<0.04) 
for that of the grafted ulna.  However, there was not a significant difference between the 
angles at failure for the grafted ulna as compared to the ungrafted ulna.  
 
 Maximum Torque (Nm) Angle at failure (rad) 
 Ungrafted Grafted Ungrafted Grafted 
Rabbit No.     
1 13.4 16.457 0.43 0.195 
2 5.359 25.099 0.285 0.608 
3 3.92 18.652 0.249 0.541 
Mean ± SD 7.56 ± 5.11 20.07 ± 4.49 0.32 ± 0.10 0.45 ± 0.22 
p 0.04* 0.43 
*indicates significant difference 
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Chapter 4 
Discussion 
 
4.1 In-Vitro 
 
Through in-vitro testing, the porous, resorbable, bioactive SCPC material was found to 
possess both the physical and biological characteristics required to make it a suitable 
carrier system for the delivery of rhBMP-2 in a segmental bone defect. The SCPC 
material demonstrated high porosity and large pores that were interconnected.  
Compression testing showed that although the material was porous, the mechanical 
strength was similar to that of trabecular bone. Upon immersion in a physiological 
solution, the composite slowly degraded while at the same time a HA layer precipitated 
onto its surface.  After loading the SCPC with rhBMP-2, the hybrid demonstrated a 
sustained release profile for 14 days in a physiological solution.  
  
4.1.1 Material Characterization 
 
SEM micrographs of the bioactive SCPC samples, processed by the Z-Corp 3-D printer 
and then thermally treated, showed the samples to be highly porous, providing a large 
surface area for enhanced tissue ingrowth (Figure 3.1.1 (a-d)).  The interconnectivity of 
the pores creates a scaffold that allows for cell and nutrient migration throughout the 
entire SCPC sample. If the pores are not interconnected, the cells can only survive at the 
surface of the sample, thus vascular and bone ingrowth will never occur.  
 
Since the viability of the regenerated bone depends upon the rate of vascularization it is 
critical that the scaffold be porous.  In fabricating a biomaterial to replace bone, the intent 
is for the internal structure of the scaffold to mimic that of bone.  The porosity of cortical 
bone ranges from 5% to 30% while cancellous bone porosity ranges from 30% to 90% 
[40].  The high porosity of SCPC, 44-54%, facilitated the ingrowth of fibrovascular tissue 
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that then ossified and the large pore size range (4 nm-356 µm) of the SCPC scaffold 
allowed for cell invasion, vascularization, and nutrients to reach the invaded cells so that 
bony ingrowth and osseous integration could occur (Figure 3.3.2 (a-b)). Although 
initially it was weaker from a structural standpoint, the porous SCPC material has an 
advantage over a solid material in that the pores facilitate the ingrowth of fibrovascular 
tissue that then ossified.  On the other hand, a nonporous implant would not allow for the 
invasion of blood vessels and cells due to its compact structure.  
 
A previous study showed that mineralized bone growth into porous implants requires a 
minimum interconnective pore size of 100 µm, the ingrowth of osteoid tissue requires a 
minimum pore size between 40 and 100 µm, and the ingrowth of fibrous tissue requires a 
minimum pore size between 5 and 14 µm [41]. However, another study reported that not 
only a pore size of greater than 50 µm is necessary, but the interconnections play an 
important role in bone formation as well [42]. That study reported that to allow for cell 
penetration the interconnections size must be greater than 20 µm.  Yet, if a material is 
resorbable, its pore and interconnection sizes will be modified by degradation upon 
contact with a physiological solution. For the SCPC scaffold, although the initial pore 
size range was 4 nm-356 µm, and the interconnections range was from 10 µm-50 µm, the 
immediate resorption that took place in a physiological solution increased this pore size 
range and interconnection size, and synergistically increased the pathways for cell 
invasion and vascularization to take place. 
 
Different thermal treatment temperatures of the SCPC composite showed that for 
different temperatures, the overall pore and interconnection sizes remained very similar.  
However, the distribution of these pore sizes was affected by the thermal treatment.  The 
pore size ranges that were shown to be affected by the thermal treatment were 10 µm-25 
µm and 25 µm-100 µm (Table 3.1.2).  In addition, as the sintering temperature was 
increased, the porosity percent was decreased.  This was due to a greater amount of 
fusion between the particle edges, and although the pore sizes were not changed, the 
porosity percent was decreased with increasing temperature.  The decrease in the porosity 
percent of the SCPC is directly related to the surface area, which also decreased with 
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increasing thermal treatment temperature.  Nevertheless, due to SCPC being a resorbable 
biomaterial, the differences in porosity and pore size distribution due to different thermal 
treatment temperatures are negligible.  Upon immersion in a physiological solution, the 
material begins to be resorbed and the pore sizes and porosity immediately changed.  
 
4.1.1.1 Hydroxyapatite Layer 
 
Moreover, the high porosity of SCPC provided a high surface area in contact with tissue 
fluids and cells, which in turn enhanced the dissolution/precipitation reactions at the 
material surface, leading to the formation of a HA layer (Figure 3.2.3 (a-c)).  The 
dissolution of the SCPC in-vivo occurred in two ways, solution-mediated resorption and 
cell-mediated resorption.  The solution-mediated resorption involved the 
dissolution/precipitation reaction that occurred as the exchange of ions took place 
between the SCPC and the physiological solution.  The cell-mediated resorption involved 
the stimulation of osteoclastic resorption of SCPC as seen in Figure 3.3.2 (a). To meet the 
requirements of skeletal growth and mechanical function, bone constantly undergoes 
dynamic remodeling by a coupled process of bone resorption by osteoclasts and 
reformation by osteoblasts. This cell-mediated resorption also occurred upon 
implantation of the SCPC implant in rabbit ulna defect; osteoclasts broke down the SCPC 
while the osteoblasts formed new bone in its place (Figure 3.3.2 (a)). 
 
Immersion of SCPC in a physiological solution led to formation of an HA layer, which 
precipitated onto its surface, as shown by FTIR (Figure 3.2.2 (a-c). The formation of this 
HA layer is essential to new bone formation because hydroxyapatite’s chemical and 
crystallographic structure is very similar to that of bone mineral. When immersing a 
biomaterial, such as SCPC, in a physiological solution the surface chemical reactions 
result in the formation of this HA layer to which bone can bond more readily. Therefore, 
the essential requirement for a biomaterial to bond to living bone is the formation of a 
bone-like apatite layer on its surface in-vivo. One previous study has proven that the SBF, 
having almost the same ionic concentration as human blood plasma, can reproduce the 
surface changes in-vivo [39]. In addition, the precipitation of a HA layer after immersion 
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in SBF has been widely used to assess the degree of bioactivity of a biomaterial [22].  
Thus, investigating the biological behavior of bioceramics in SBF is considered to be the 
most efficient method to authenticate their bioactivity in the body environment.  
 
4.1.1.2 Mechanical Strength 
 
In replacing bone in a segmental defect, it is important for a porous implant to have initial 
mechanical strengths that will allow it to withstand loading until bone regeneration can 
occur.  A biomaterial must demonstrate equivalent mechanical properties to the type of 
bone being replaced, whether it is trabecular or compact bone.  However, by virtue of the 
need of porosity and resorbability there would be a trade off between the mechanical 
strengths and the porosity.  This is due to the compressive strength being inversely 
proportional to the volume percentage of porosity.  Mechanical testing of the thermally 
treated SCPC material confirmed that although the samples were porous, their 
compressive strengths (5-15 MPa) were similar to that of trabecular bone (2-12 MPa) 
(Table 3.1.3).  The high compressive strength of SCPC was due to the high thermal 
treatment temperature of the SCPC samples which caused the particle edges to fuse with 
each other during the sintering reaction.   As the thermal treatment was increased the 
mechanical strengths of the material also increased, due to greater fusion of the SCPC 
particle edges.  However, this increase in strength corresponded to a decrease in porosity 
as previously mentioned. Nevertheless, the compressive strengths of the SCPC samples 
were similar to trabecular bone, but less than that of compact bone which has a 
compressive strength of (100-220 MPa).  Therefore if it used for cortical bone 
replacement, as in this study, an external fixation device should be used to provide the 
initial support.  Then as the porous SCPC implant undergoes biodegradation, it is slowly 
replaced by bone.  The strength of the implant in the defect will gradually increase as the 
new bone grows into the porous network of the SCPC implant.  Although a nonporous or 
compact scaffold would have higher mechanical properties, as previously stated, a solid 
material would not allow for the invasion of cells and blood vessels that are necessary for 
new bone to form.  In addition, it used as a carrier for growth factors, a solid scaffold 
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would cause immediate release of the growth factor, instead of a desired controlled 
release. 
 
4.1.1.3 Geometry 
 
For a bone tissue engineering scaffold to successfully regenerate bone in a defect and be 
capable of supporting cell proliferation, its internal as well as external geometry must 
replicate natural bone [40]. By fabricating the SCPC using the Z-Corp processing, a SFF 
technology, a scaffold that mimics the internal and external architecture of natural bone 
was created.  Upon implantation in-vivo this scaffold acted as a placeholder for the 
induction of new bone.  As can be seen in Figure 3.3.1 (c-d), bone mass developed in the 
size and shape of the Z-Corp processed SCPC scaffold.  The external shape and 
topography of natural bone is very complex; no bone in the body is perfectly square or 
cylindrical.  This is why it is necessary to fabricate bone tissue engineering scaffolds that 
exactly replicate bone.  Z-Corp processing of the SCPC material allowed for this.   
 
4.1.2 rhBMP-2 Release Kinetics 
 
When a bone tissue engineering scaffold is used as a carrier for BMP, it must have a 
controlled release of the BMP, so that the protein is retained at the grafted site for a 
period of time sufficient to stimulate cell differentiation and induce bone formation.  It is 
desirable to have a bulk release of BMP initially, followed by a more gradual release 
thereafter [20]. Many studies have investigated the ability of calcium phosphate ceramics 
to serve as a delivery system for BMP [9, 43, 44]. However, these studies showed that the 
porous ceramic implants demonstrated a very limited release of rhBMP-2.  This means 
that almost all of the rhBMP-2 was maintained at the cement surface, inhibiting the 
protein from exerting its biological action. In our study, upon immersion in a 
physiological solution, the SCPC-rhBMP-2 hybrid implant demonstrated a continuous 
release of rhBMP-2 for 14 days (Figure 3.1.4).  As compared to HA, the SCPC implant 
had a greater release of rhBMP-2 over the 14 day period.  Due to the high porosity and 
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the nanopores of the SCPC implant, the protein had a large surface area with which to 
adsorb.  The nanopores (Figure 3.1.1 (d)) allowed for a greater surface area for protein 
adsorption, they provided protective pockets for the adsorbed protein, and enhanced the 
sustained release of rhBMP-2 [45]. This sustained release of rhBMP-2 by SCPC was 
demonstrated in-vivo, where the SCPC implant maintained the growth factor at the 
defect, stimulating osteoblast differentiation and new bone formation (Figure 3.3.2 (a)).  
 
4.1.3 Interaction of SCPC with SBF 
 
4.1.3.1 Effect of Immersion Duration 
 
ICP analyses indicated that after immersing the resorbable SCPC samples in SBF the Ca 
concentration of the SBF decreased linearly until 12 hours while the P, Si and Na 
concentrations of the SBF increased (Figure 3.2.1 (a-d)).  Figure 3.2.1 (a) shows the 
initial decrease in the Ca concentration which was due to the precipitation of a HA layer 
onto the surface of the SCPC as has been confirmed by FTIR (Figure 3.2.2 (a-c)) and 
SEM (Figure 3.2.3 (a-f)).  FTIR analyses showed that after 12 hours SCPC had 
developed a layer consisting of small HA crystallites that completely covered its surface.  
SEM analyses showed the homogenous distribution of these HA crystals, having a size of 
1 µm, on the surface and in the pores and interconnections.  Another study found similar 
results when the biomaterial hydroxyapatite was immersed in SBF [46].  They found that 
after 1 day the hydroxyapatite surface was completely covered by a layer of precipitates 
that nucleated on the surface and in the pores and chasm.   
 
For SCPC, the precipitation of the HA layer occurred concurrently with the initial 
dissolution of the ions from the samples.  The previously mentioned study with the 
hydroxyapatite biomaterial also found that the dissolution of Ca and P and the 
precipitation of calcium phosphate occur concurrently, leading to the HA layer on its 
surface.  Another study investigated the dissolution behavior of HA/BG in SBF [47]. This 
study found that at the early stage of immersion, the dissolution preceded faster than the 
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eventual precipitation of an apatite layer.  In the case of SCPC, as the immersion time 
increased beyond 12 hours the Ca concentration of the SBF began to plateau.  This was 
due to an equilibrium being reached between the precipitation/dissolution interaction of 
the SCPC sample and the SBF.  This equilibrium exchange of ions indicates the constant 
degradation of the resorbable SCPC implant being replaced by a bone-like apatite layer 
that formed after just 12 hours of immersion in SBF.  In contrast, the study with the 
hydroxyapatite biomaterial did not show an equilibrium exchange of ions until after 14 
days of immersion.  
 
In contrary to the initial decrease in the Ca concentration of the SBF, the P concentration 
initially increased (Figure 3.2.1 (b)).   The increase in P concentration of the SBF may be 
due to the fact that not all P ions dissolved from the SCPC sample were consumed in the 
formation of the HA surface layer.  SCPC initially has a Ca to P ratio of 1, however when 
Ca and P precipitated after dissolution they precipitated as hydroxyapatite which has a Ca 
to P ratio of 1.67. Therefore, the exchange of the Ca and P ions between the SCPC 
sample and the SBF resulted in excess P ions in the SBF that were not involved in the 
mechanism of the formation of apatite on the SCPC surface.  The P concentration began 
to level off after 12 hours of immersion.  For the remaining immersion time, the P 
concentration slightly decreased and, like the Ca concentration, began to plateau.  This 
again indicates that equilibrium in the precipitation/dissolution interaction had been 
reached.  The study involving the hydroxyapatite biomaterial showed an initial increase 
in P concentration of SBF, and then a decrease.  Like the Ca ions, an equilibrium 
exchange of P ions for the hydroxyapatite biomaterial was not reached until 14 days of 
immersion. 
 
 As the immersion time increased the amount of CaP precipitated onto the SCPC sample 
also increased, creating a dense HA layer on the surface. Moreover, the FTIR spectra 
after 12 hours also showed signals characteristic of a carbonate hydroxyapatite layer that 
was noted by the peaks for P─O at 560, 605, and 1030 cm-1 (Figure 3.2.2 (a-c)).  Other 
studies have attributed these same peaks as the P─O bonds of HA [45, 48-51]. This, in 
conjunction with the ICP results, demonstrates that the dissolution of the SCPC in 
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physiological solution was followed by the formation of a hydroxyapatite layer known to 
stimulate bone cell function.  Similar studies of the effect on the interaction of 
hydroxyapatite and bioactive acrylic-glass samples with SBF showed that after 24 hours 
and 4 days, respectively, there was a HA layer formed on the surface [46, 52]. The 
formation of the HA layer on the SCPC samples after only 12 hours shows the higher 
bioactivity of the material.  In conjunction, SEM micrographs confirm that after 12 hours 
of immersion in SBF, there is formation of a HA layer on the SCPC samples.  
Micrographs after 1 day of immersion show a denser HA layer formed that fully covered 
the surface of the SCPC samples. 
 
It is also important to note that when the dissolution of the ions from the SCPC sample 
takes place, they do not only dissolve from the outer surface of the SCPC but also 
throughout the sample.  Due to the sample being porous, the SCPC sample can degrade 
evenly throughout and the ions from the SBF precipitate throughout the entire SCPC 
sample, inside and out.  This means that the formation of an HA layer not only occurs on 
the outside surface of the SCPC sample, but also throughout the network of pores that 
make up the SCPC sample. 
 
The ICP analyses indicated that the Si concentration of the SBF was initially very low but 
showed a linear increase for the duration of the SCPC sample being immersed in the SBF 
(Figure 3.2.1 (c)).  This increase in Si concentration of the SBF reflects the dissolution of 
Si ions from the SCPC sample into the SBF.  Analysis of the SCPC surface chemistry by 
FTIR showed that before immersion in the SBF, the SCPC samples had strong Si─O 
peaks due to the silica-rich composition.  After 12 hours of immersion in the SBF, these 
peaks were no longer distinct. This correlates with the ICP results which showed an 
increase in the Si concentration of the SBF after 12 hours.  This proves that the Si was 
released from the SCPC sample into the immersion solution.  Previous studies reported 
that the high bioactivity of silicon [53] which when released nucleated HA formation 
apart from the SCPC samples.  In addition, this dissolution was also beneficial in that as 
the silica-rich samples released the silicon, it allowed for the HA layer to form on the 
surface in its place. In the current study it was found that the dissolution from the SCPC 
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allowed the Si ions to nucleate apatite formation away from the SCPC sample as well as 
allowing the Ca and P ions to create an HA layer on and throughout the SCPC in its 
place.  Previous studies that have used polymers as a tissue engineering scaffold, 
“impregnate” their material with sodium silicate gel, which acts as a nucleating agent to 
promote the nucleation and growth of a HA layer on the polymer surface [54, 55]. On the 
other hand, one study reported that apatite cannot precipitate on silica-rich surfaces [56]. 
Consequently, the dissolution of the Si from the SCPC samples not only nucleated apatite 
formation away from the implant, but it in its absence allowed for apatite formation on 
the surface of the implant.  
 
SEM analysis after immersion in SBF confirms the morphology changes of the SCPC 
surface that were demonstrated in the ICP and FTIR results.  Micrographs show that 
these surface modifications were in the form of HA crystal deposits that cover the surface 
of the SCPC scaffold and on the surface.  
 
4.1.3.2 Effect of Thermal Treatment Temperature 
 
The thermal treatment temperature of the SCPC samples had a significant effect on the 
interaction between the SCPC and SBF. The significant differences in the corrosion 
behavior of the SCPC disks are due to the different thermal treatment they were subjected 
to.  Each of the thermal treatments causes the SCPC disks to have diverse crystalline 
phases.  Each of the phases responds differently to being immersed in the SBF and these 
differences are shown in the varied ionic concentrations of the SBF at each of the 
immersion time periods.  ICP results show that with respect to P, and Si, ion 
precipitation/dissolution, the SCPC samples thermally treated at 850 ºC demonstrated a 
significantly higher corrosion rate than those samples treated at 800 or 900 ºC (Figure 
3.2.2 (a-c)).  In conjunction, FTIR spectra showed that after immersion in SBF, the 
appearance of peaks for P─O, observed at 560, 605, and 1030 cm-1, which are 
characteristics of carbonate hydroxyapatite, were more prominent for those samples 
thermally treated at 850 ºC as compared to the other thermal treatment temperatures.  
Furthermore, SEM micrographs confirm the formation of a HA layer, showing that SCPC 
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samples thermally treated at 850 ºC have a denser apatite layer formed with larger apatite 
crystals (Figure 3.2.3 (a-f)).  The significant differences in the corrosion behavior of the 
SCPC samples were due to the different thermal treatment temperatures they were 
subjected to.  Each of the thermal treatments caused the SCPC samples to have diverse 
crystalline phases.  Each of the phases responded differently to being immersed in the 
SBF and these differences are shown in the varied ionic concentrations of the SBF at 
each of the immersion time periods.  
 
The results of the Material Characterization together with the Interaction of SCPC with 
SBF show that the SCPC processed with the Z-Corp 3-D printer is highly porous with a 
large surface area and high compression strength and is not only bioactive but is also 
resorbable.  All of these attributes combined form a scaffold that can serve as a tissue 
engineering substitute for autologous bone implant.  
 
4.2 In-Vivo 
 
After obtaining successful results through the in-vitro testing of SCPC, the porous, 
resorbable, bioactive biomaterial was tested in-vivo as a carrier for rhBMP-2.  The SCPC-
rhBMP-2 hybrid prepared by a rapid prototyping technique enhanced rapid bone 
regeneration in a segmental bone defect in the ulna of rabbit.  Implantation of the SCPC-
rhBMP-2 hybrid into a segmental defect created in the ulna of rabbit showed that after 3 
months the resorbable implant had been replaced with new bone and the defect was 
almost completely reconstructed. Torsional testing demonstrated that the bone strength 
was returned to normal.  Histological evaluation showed that the SCPC-rhBMP-2 hybrid 
had been replaced by mature bone that has directly formed on the implant surface. These 
results indicate that the SCPC-rhBMP-2 can serve as a tissue engineering alternative to 
autologous bone grafting. 
 
 78
4.2.1 Radiographs 
 
CT scans of the rabbit ulna allowed for a non-invasive way to track the progress of the 
healing of the segmental defect.  After 4 weeks of implantation, significant bone healing 
and full implant integration with bone can be observed in the defect grafted with the 850 
ºC thermally treated SCPC-rhBMP-2 hybrid (Figure 3.3.1 (a-b)).  In addition, direct 
apposition of bone onto the implant surface can be seen.  After just 4 weeks of 
implantation, the resorbable SCPC-rhBMP-2 hybrid had induced the formation of newly 
formed bone that replaced about 65% of the initially 10 mm long critical sized defect.  
This rapid healing demonstrates the high bioactivity of the SCPC and the osteoinductive 
ability of the rhBMP-2 to differentiate mesenchymal stem cells into osteogenic cells.  In 
addition, due to the SCPC-rhBMP-2 scaffold being processed using the Z-Corp 3D 
printer and made into an exact replica of the defect, this allowed for an intimate contact 
between the bone and the implant.  Not only did this allow for rapid integration of cells, 
but the regenerated bone mass also was formed in the exact size and shape of the natural 
bone.  
 
Digital images of the rabbit ulna grafted with the SCPC-rhBMP-2 hybrid harvested after 
16 weeks of implantation showed almost complete healing of the defect (Figure 3.3.1 (c-
d)).  Due to the abundant new bone formation, it was barely distinguishable where the 
implant had originally been.  Figure 3.3.1 (c) showed the high vascularization of the 
regenerated bone, indicating the integration of blood vessels throughout the entire 
original defect.   
 
4.2.2 Histology 
 
Histological analysis showed newly regenerated bone with a fully developed Haversian 
system.  As shown in Figure 3.3.2 (a-b) the regenerated bone was highly vascularized and 
osteocytes could be seen in the mature mineralized tissue just 12 weeks after implantation 
of the SCPC-rhBMP-2 hybrid.  Remnants of the SCPC biomaterial were incorporated in 
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the newly formed bone, with direct bone apposition on its surface. Differentiated 
osteoblasts were observed actively regenerating bone. A study using a combination graft 
of rhBMP-2/PLGA in a segmental defect, histologically showed only the abundance of 
immature bone after 16 weeks of implantation [57]. Another study using PLGA-coated 
gelatin sponge as a carrier for rhBMP-2 in a segmental defect showed similar formation 
of bony bridging by newly formed bone after 16 weeks [16]. However, a study that used 
porous polyurethane, upon histological evaluation, showed macrophages and giant cells 
getting organized around the edges of the porous polymer [8]. The histological evaluation 
of the SCPC-rhBMP-2 hybrid showed no signs of an adverse inflammatory reaction.  The 
histological results indicate that the newly formed bone inside the defects grafted with 
SCPC-rhBMP-2 scaffold has all the morphological characteristics of mature bone. 
 
4.2.3 Torsional Testing 
 
To regain complete functionality of bone the new regenerated bone needs to have the 
same mechanical strengths as natural bone.  As new bone is formed in place of a defect, 
the goal is to return the strength of the bone back to normal.  Torsional strength of the 
rabbit ulna grafted with the 900 ºC thermally treated SCPC-rhBMP-2 hybrid was tested in 
comparison to the ungrafted ulna.  Restoration of maximum torque and angle at failure of 
the regenerated bone to comparable levels of natural bone was seen after 12 weeks of 
implantation (Table 3.3.3).  Due to the high porosity and bioactivity of SCPC and the 
osteoinductive capabilities of rhBMP-2, bone induction occurred rapidly and the 
regenerated bone became mechanically equivalent to the original bone.  Although direct 
comparison between studies is difficult due to differences in experimental techniques, the 
results in this study show a similar time frame in the restoration of bone strength. Kokubo 
et al. used poly[L-lactide-co-glycolide]copolymer-coated gelatin sponge as a carrier for 
BMP in a segmental defect and achieved restoration of maximum torque and angle at 
failure to the intact levels after 32 weeks of implantation [13]. However, it was found in 
this study that the implant that had initially been processed into a block caused an 
increase in diameter of the regenerated bone.  This was not found in our study because 
the SCPC-rhBMP-2 was fabricated using a Z-Corp 3D printer which allowed for an exact 
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replica of the defect to be made. Another study, using resorbable calcium-phosphate 
particles in a segmental defect, found that after 12 weeks, the bone formed in the defect 
had relatively poor mechanical strengths due to the resorption of the particles taking 
place before complete remodeling of the bone could occur [6]. The high porosity, 
bioactivity, and osteoinductive behavior of the SCPC-rhBMP-2 hybrid induced the rapid 
formation of bone, which allowed for the regenerated bone to regain complete 
functionality after just 12 weeks of implantation. 
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Chapter 5 
Conclusion 
 
Bioactive resorbable SCPC, processed using a 3D rapid prototyping technique, created 
highly porous scaffolds with interconnected pathways to allow for cell and blood vessel 
invasion.  In-vitro testing of the SCPC material indicated that the material had high 
mechanical properties.  In addition, when immersed in physiological solution, the SCPC 
material demonstrated controlled dissolution/precipitation reactions that led to the 
formation of a biological hydroxyapatite surface layer known to stimulate bone cell 
function. When loaded with rhBMP-2, the SCPC-rhBMP-2 hybrid showed a sustained 
release of the growth factor.  In-vivo testing of the SCPC-rhBMP-2, prepared by a rapid 
prototyping technique to create an exact replica of a segment of the rabbit ulna, showed 
excellent bone regeneration.  This hybrid enhanced bone regeneration in a segmental, 
load-bearing bone defect in the ulna of rabbit. Torsional testing of the ulna demonstrated 
the restoration of complete functionality after just 12 weeks of implantation.  Histological 
evaluation showed differentiated osteoblasts and osteocytes in the mature mineralized 
tissue. The enhancement of complete bone regeneration after 16 weeks was attributed to 
the high bioactivity and resorbability of the material.  Both the in-vitro and in-vivo results 
indicate that the porous, resorbable, bioactive SCPC-rhBMP-2 hybrid can serve as a 
tissue engineering substitute for autologous bone implant. 
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